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Abstract
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype 
lacking the three hormonal receptors namely estrogen receptor, progesterone recep-
tor and HER2 receptor, and the only treatment option available for TNBC is che-
motherapy. Chemotherapy lacks specificity since it acts on normal healthy cells as 
well resulting into secondary diseases in TNBC patients. In addition chemotherapy 
poses recurrence and relapse issues due to the development of chemoresistance 
among TNBC patients. Immunotherapy remarkably immune checkpoint inhibi-
tors show a great therapeutic potential in TNBC. As TNBC contain an increased 
TILs (tumor infiltrating lymphocytes) infiltration making it more suitable as a 
therapeutic target anti-tumor immune strategy. Moreover, evidences have indicated 
that chemotherapy upregulates the anti-tumor immune response in TNBC. As a 
result, a combination of immunotherapy with chemotherapy may increase the 
overall relapse and recurrence free survival of TNBC patients. Therefore, in this 
chapter we will focus on how the immunotherapy works in TNBC, their effects and 
consequences. We will further be discussing the clinical studies and the importance 
of immune checkpoint inhibitors (ICIs) in combination with various therapeutic 
agents and target. Further, we will explore the processes involved.
Keywords: TNBC, PD-1, immunotherapy, immune checkpoints,  
immune checkpoint inhibitors, epigenetics, CTLA-4, oncolytic virus
1. Introduction
Triple negative breast Cancer (TNBC), is an aggressive breast cancer subtype 
characterized by the lack of hormone receptors; estrogen receptor, progesterone 
receptor and HER2 receptor accounting for about 15–20% of all breast cancers, 
with chemotherapy available as the prime systemic therapy. The treatment results 
into low median overall survival with earlier recurrence and metastasis posing to 
be a great hurdle in the control of this disease [1]. Therefore, improved therapies 
are urgently needed. Immunotherapy has prolonged survival in other solid tumors 
and represents a promising treatment strategy for TNBC (Figure 1). In the recent 
days, targeting immune checkpoint inhibitors are noted immunotherapeutic agents 
that are known to block immunosuppressive receptors like PD-1 (anti-programmed 
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death receptor-1) and CTLA-4 (cytotoxic T lymphocyte antigen-4), which are 
significantly involved in tumor directed immune responses [2]. Moreover, several 
characteristics of TNBC make immunotherapy to be corner stone of the modern 
therapeutic regimens such as the presence of TILs (Tumor infiltrating Lymphocytes 
(TILs). The TILs are associated with better therapeutic responses increasing the 
disease free survival and overall prognosis in TNBC in comparison to other breast 
cancer subtypes. The presence of TILs as well acts as predictive biomarkers for 
immunotherapy response that makes immunotherapy more intriguing for TNBC 
treatment [3–5]. Besides, TNBC are known to possess higher PD-L1 expression 
levels on both tumoral and immune cells that are likely to respond to the immune 
checkpoint inhibitors (ICIs) such as pembrolizumab, nivolumab (monoclonal anti-
bodies against PD-1), Ipilimumab (antibody against CTLA-4) and Atezolizumab, 
Avelumab (antibody against PD-L1) [2, 6, 7]. In addition, the presence of sig-
nificant number of non-synonymous mutations in TNBC generate neo-antigens 
specific to tumors that activate robust anti-tumor immune responses that can be 
synergistically utilized by the current immunotherapeutic agents like ICIs [8–10]. 
Nevertheless, the presence of higher levels of BRCA1 and BRCA2 mutations giving 
rise to unstable genetics acts as a significant predictive marker for immunotherapy 
response [11].
The immune system plays a dual role in a way that it not only is involved in 
tumor initiation and progression but also acts significantly in the recognition and 
destruction of cancer cells. The later generates a tumor-directed immune response 
involving cytotoxic T lymphocytes [12, 13]. For cancer progression the tumors are 
known to evade the anti-tumor immune response by certain array of mechanisms 
like activation of pro-tumor-polarized innate inflammatory cells, activation of 
humoral immunity, suppression of tumor-specific antigens, infiltration by Th2 T 
cells, absence of major histocompatibililty complexes (MHC) on tumor cell surface 
and negative immune checkpoint inhibitor expression by tumor cells [13, 14]. These 
mechanisms followed by tumor cells to evade immune responses are known as hall-
marks of cancers as these work in concordance to suppress the anti-tumor response 
and promote cancer progression. Therefore, in order to bring cancer control strate-
gies targeting these specific mechanisms are utilized in immunotherapy to bring in 
control the tumor progression (Figure 2) [15].
Figure 1. 
Represents the available treatments for TNBC (triple negative breast cancer).
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Therefore, actively manipulating the immune system for TNBC treatment repre-
sents to be an attractive strategy as this particular breast cancer subtype has lacked 
in terms of extensive clinical management. In view of that, immune checkpoint 
inhibitors (ICIs) has revealed promising results in TNBC patients by substantial 
improvement in TNBC patients overall prognosis. However, the focus of this field 
is to recognize the immunogenic identity of patients for the clinical management 
of patients and in specific to identify specific therapeutic agents to target tumor 
microenvironment [14]. Nevertheless, the utilization of current therapeutics like 
chemotherapy, radiotherapy in combination with immunotherapy will augment the 
immunotherapeutic response as they enhance tumors mutational load, downregu-
late immune suppression by tumor microenvironment and boost antigen presenta-
tion by tumor cells, henceforth making tumors more prone to immunotherapy 
(Figure 2) [16–18]. Interestingly, many clinical trials are underway and some have 
revealed that combination of immunotherapy with other therapeutic agents besides 
chemotherapy and radiotherapy has enhanced the patient responses in terms of 
progression free survival and standard of care [19, 20].
2. Role of immunotherapy in TNBC
The immune system is known to kill tumor cells by a process called immuno-
surveillance in which the immune cells target and kill the tumor cells by two ways; 
either directly or indirectly by releasing soluble chemicals. The cells involved are 
cytotoxic T lymphocytes (CTL), dendritic cells (DC), macrophages, Natural killer 
cells (NK) etc. As described earlier, the cancer cells are known to evade the host’s 
immune responses in that the host’s immune system identify the tumor cells as self 
due to which the tumor cell is favored to escape, grow, proliferate and metastasize 
to distant organs. Furthermore, as the tumor develops, they modify the immune 
cells for their own benefit like they modify TAMs and recruit them to the tumor 
Figure 2. 
Overview of involvement of immune system in TNBC with combination treatment options; A. Represents on 
recognition of the antigen from the tumor cell the immune cell destroying the tumor cell B. Shows that how 
PD-L1 from the tumor cell interacts with PD-1 and this binding causes T cell exhaustion and helps the tumor 
cell evading the immune response.
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microenvironment to release chemicals that suppress the immune system further 
enhancing the suitable environment for the tumor cells to survive and proliferate 
[21]. Therefore, targeting this strategy of immune evasion by cancer cells i.e. modu-
lating the immune system is imperative for the development of therapeutics against 
tumors. In addition, the currently available treatment options like chemotherapy, 
radiotherapy are known to be ineffective because of the induction of relapse and 
recurrence, development of resistance, lack of specificity in addition to side effects 
and toxicity that leads to tumor development and metastasis in secondary sites. 
In view of this, immunotherapy is considered to be the most reliable therapeutic 
approach in terms of target specificity by targeting different immune cells, their 
functional attributes to block the development and spread of aggressive tumors 
and as a non-toxic anti-cancer therapeutic strategy. Moreover, immunotherapy has 
emerged as the fourth most important treatment for cancer after surgery, chemo-
therapy and radiotherapy and has shown effective treatment responses among 
patients (Figure 2) [22].
Recently immunotherapy was developed as an effective treatment strategy 
against cancers with a goal to design therapeutics that can effectively enhance  
the immune system in terms of its specificity and strength its response towards the 
evading tumors [23]. In the year 2018, James P. Allison and Tasuku Honjo won the 
Nobel Prize in Physiology and Medicine for discovering a treatment for cancer by 
downregulating the negative immunomodulation. In their study, they demonstrated 
that the immune checkpoints like PD-1 (programmed cell death protein1) and 
CTLA-4 (cytotoxic T lymphocytes associated protein 4) act as “brake” in immune 
system as they may reactivate T cells by immune checkpoint inhibition, hence elicit-
ing an improved immune response against malignant tumors [24]. The significance 
of immune checkpoint inhibitors as potential therapeutics has proven in various 
studies. Many studies have revealed that PD-1 inhibition promotes effective immune 
responses against cancers [25]. Accumulating studies on PD-1 signaling suppression 
has revealed that the patient’s clinical response to immunotherapy depends upon the 
effectiveness of T-cells to penetrate the tumor [26]. In the past decade many immune 
system components have been explored as adoptive immunotherapies like cytotoxic 
T cells, TILs, anti-CD3 monoclonal antibody-induced killer cells and activated killer 
cells but they showed less efficiency as therapeutics because of their low anti-tumor 
functions [27]. However, an in-vitro study has suggested the cytokine-induced 
killer (CIK) cells to a promising target for utilization as immunotherapeutic target 
because of its higher proliferation rate, hence more effectiveness towards eradicating 
cancer [21]. CIKs contribute to sturdy cytolytic activities towards tumors as these 
are non-major Histocompatibility complex- restricted cells that can express both 
natural killer cell and T cell markers such as CD56 and CD3 [28]. Furthermore, CIKs 
are known to improve the immune response in patients by regulating and therefore, 
increase the efficacy of immune function [29]. However, study of CIK cell therapy 
in breast cancer, particularly in TNBC has been limited. Despite that evidences have 
reported that the association of CIKs with chemotherapy may result in synergistic 
effects, supported by an in-vitro and in-vivo study against cancer stem cells that 
were resistant to chemotherapy. Therefore, strongly suggests that combined therapy 
might improve therapeutic efficacy in patients having TNBC, as chemotherapy has 
shown to regulate the patient’s immune status [30].
3. Immune checkpoints in immunotherapy
Immune checkpoints comprise of a collection of different regulatory proteins 
in the adaptive system that regulate the immune system functions i.e. anti-tumor 
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activity and self-tolerance. They are known to function by coordinating the fre-
quency, magnitude and type of immune response either via positive or negative 
regulation. There are mainly two immune checkpoint s studied namely PD-1/PD-L1 
and CTLA-4, as their presence in the TME prevents to elicit an anti-tumor response 
via negative regulators of immune activation [31].
3.1 PD-1
PD-1 also known as CD279 was first discovered in the year 1992 [32]. It is a 
55 kDa transmembrane protein comprising of 288 amino acids with an extracel-
lular N-terminal domain, a cytoplasmic tail at each N and C end, a transmem-
brane domain respectively with two tyrosine bases [33]. PD-1 are expressed on 
a number of immune cells like macrophages, B lymphocytes, activated T cells, 
Dendritic cells, natural killer cells, activated T cells and monocytes. However, 
they are highly expressed on specific T-cells. PD-1 is known to act as an inhibitor 
of both innate and adaptive immune responses [34]. It is supposed its transcrip-
tion is triggered by many transcription factors such as NOTCH, nuclear factor of 
activated T cells (NFAT), Interferon (IFN), Forkhead box protein (FOXO1) and 
interferon regulatory factor 9 (IRF9) [35]. PD-1 expression is highly increased 
during acute infection and also when there happens to be leakage from cancer 
cells. PD-1 function in both beneficial and harmful manner to the immune 
system as it plays a significant role in maintaining immune tolerance by regula-
tion of the harmful and inefficient immune responses while also interfering with 
the classical protective role of immune system by negative regulation [36–38]. A 
higher PD-1 expression has been seen in TNBC patients in comparison to non-
TNBCs and has been associated with larger tumors, higher histological grades, 
increased TILs etc. [39].
3.2 PD-L1
PD-L1 is a ligand to PD-1. It belongs to the B7 series and is also known as 
B7-H1 and CD279. It is a transmembrane glycoprotein as is PD-1, containing 
Figure 3. 
Represents PD-1 mediated T cell inhibition. The binding of PD-L1 expressed on tumor cells binds to its receptor 
PD-1 on T cells delivering an inhibitory signal to T cells that lead to T cell exhaustion and ineffective T cells.
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290 amino acids with IgC domains in its extracellular portion. The cells that 
express PD-L1 include: activated B and T cells, epithelial cells, macrophages and 
dendritic cells, particularly at the time of inflammatory responses. The PD-L1 
expression is connected with the production of Th1 cytokines, presence of CD8 T 
cells, interferon, other chemical factors as well as expression of specific genes i.e. 
all these are responsible for the over expression of PD-L1 and further malignant 
disease progression, which we will be discussing later in the chapter. Therefore, 
inhibiting the particular pathways for instance, on activation the NK and T cells 
secrete interferon-gamma that induces PD-L1 expression on the cells including 
tumor cells etc. has been shown to promote strong antitumor responses among 
patients.
The PD-L1 is utilized by the opportunistic tumor cells to evade immune 
response by mimicking the “Adaptive immune process”. Furthermore, PD-L1 is 
known to act as a pro-tumorigenic factor activating survival and proliferating 
signaling pathways by receptor binding, hence implicating its greater role in 
tumor proliferation and metastasis (Figure 3). In addition, PD-L1 also acts in a 
non- immune pattern by inducing epithelial to mesenchymal transition exerting 
in the tumor cells stem cell like characteristics promoting metastasis and disease 
progression Table 1[41].
3.3 CTLA-4
CTLA-4 is a member of the CD28 family and is considered to be the “leader” 
of the immune checkpoint inhibitors as it potentially stops autoreactive T cells 
in the lymph nodes at the initial stages of development [42, 43]. It is the first 
immune checkpoint discovered among other immune checkpoints. It is a trans-
membrane receptor of T cells and it is a leukocyte differentiation antigen  
that regulates the immune process by negative regulation by competing and 
binding to the B7 receptor, as it is a CD28 homolog [40]. CTLA-4 plays a signifi-
cant role to prevent self-reactive immune responses particularly by increasing 
immunosuppressive Treg. Activity and downregulation of the T effector cell 
function [14].
Similarities Difference
Expressed by activated T cells CTLA-4 limits T-cell responses early in an immune response, 
primarily in lymphoid tissues; PD-1 limits T-cell responses later in 
an immune response, primarily in peripheral tissues
Regulate an overlapping set of 
intracellular T-cell signaling proteins
CTLA-4 affects Tregs functioning; the role of PD-1 on Tregs is 
unclear
Level of expression affected by 
the strength and duration of TCR 
signaling
CTLA-4 is expressed by T-cells; PD-1 is expressed by T cells and 
other immune cells
B7 receptor family members CTLA-4 ligands are expressed by professional APCs; PD-1 ligands 
are expressed by APCs and other immune cells, and can be 
inducibly expressed on non-immune cells, including tumor cells
Reduce T-cell proliferation, glucose 
metabolism, cytokine production 
and survival
PD-1 engagement interferes with more T-cell signaling pathways 
than does CTLA-4 engagement
Adapted from [40].
Table 1. 
Comparison of immune checkpoints CTLA-4 and PD-1.
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4.  Possible mechanism of action of anti-programme death receptor-1/
Ligand-1 (PD-1/PD-L1) in cancer
PD-1/PD-L1 is known to control the induction and maintenance of immune 
tolerance within the tumor microenvironment. It performs a significant role in 
cytotoxic secretion and T cell activation and proliferation in cancer to inhibit anti-
tumor immune responses in host [41]. During tumor proliferation, the PD-L1 is 
highly expressed on tumor cells that bind to the PD-1 receptor on T cells that receive 
an inhibitory signal from the PD-L1 binding i.e. to inhibit the T cell’s immune func-
tion that leads to T cell exhaustion making T cells ineffective (Figure 3).
However, monoclonal antibodies that target PD-1 and PD-L1 are being studied 
and used as these pathways are majorly taken by tumor cells to proliferate in host’s 
body that are known to typically regulate activity of T cells for their own benefit 
that is to evade the immune responses generated against them. Accumulating 
evidences has suggested that by inhibiting the binding of PD-L1 to PD-1, the anti-
tumor response is made stronger as the T cell exhaustion is reversed. Therefore, in 
view of that several monoclonal antibodies are being studied, particularly in TNBC 
like Atezolizumab, Avelumab and Durvalumab that specifically target PD-L1 and 
others such as Pembrolizumab and Nivolumab specific to target PD-1 [31].
5.  Possible mechanism of action of cytotoxic T lymphocytes (CTLA-4) in 
cancer
CTLA-4 (Cytotoxic T lymphocyte-associated protein-4), is another regulatory 
pathway of T cells. During T cell activation CTLA-4 is highly upregulated. Upon 
T cell activation, the CTLA-4 is translocated from the intracellular granules to the 
plasma membrane that further amplifies the T-cell response by regulating T-cell 
priming and activation. It inhibits the intracellular T cell activation signaling by 
competitive binding for CD80/CD86 that results in downregulation of immune 
response. Moreover, it acts through protein tyrosine phosphates 6 and 11 to suppress 
Figure 4. 
Shows CTLA-4 inhibits T cell activation thereby regulating the immune responses. Therefore, tumor cells escape 
immune response by suppressing CTLA-4.
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the TCR signal. CTLA-4 plays an important role in regulating peripheral tolerance 
that is an immunological process to prevent auto-immune responses by suppressing 
T effector cell function and further by upregulating the immunosuppressive Treg 
activity. Tregs express CTLA-4 constitutively unlike effector cells thereby acting as 
a major mechanism for immune suppression (Figure 4) [14].
Therefore, many monoclonal antibodies are currently being studied for 
instance; Tremelimumab specific for target CTLA-4 is being investigated in patients 
with TNBC. Limited research is available regarding CTLA-4, eagerly awaiting the 
need for research in discovering treatment options and other potential targets in 
TNBC treatment [31]. By inhibiting the CTLA-4 mediated response or the blockade 
of CTLA-4 results into the activation of non-specific immune cell activation and is 
connected with increased treatment-related adverse events (TRAEs). For instance, 
CTLA-4 depletion has results into rheumatoid arthritis, type I diabetes, collagen 
induced arthritis and systemic lupus erythematosus [14].
6. Other immune checkpoints under investigation
Apart from the above two immune checkpoints, a variety of other immune 
stimulatory and suppressive checkpoints are currently under investigation as 
immunotherapy targets that include; TIM-3, LAG-3, TIGIT, VISTA and BTLA-4, 
these reduce the anti-tumor immune response by regulating T cell activity like 
CTLA-4 and PD-1. Among them TIM 3, BTLA-4 and LAG-3 are implicated as T cell 
exhaustion markers in tumors same as that of PD-1. TIM 3 negatively regulates the 
cytotoxic CD8 T cells and Th1 CD4 T cells, thereby shifting the immune responses. 
TIGIT is expressed by a number of cells such as: T cells, Treg cells and NK cells 
Immune checkpoints Function
Immunoinhibitory checkpoints
PD-1 Regulates T cell activation by binding to its ligand PD-L1 and PD-L2
CTLA-4 Acts by competitive binding with the receptors and prevent the 
co-stimulatory signal thereby balancing the stimulatory signals of the 
host immune response
TIM-3 Shifts the immune response by negatively regulation of Th1 CD4 T 
cells and cytotoxic CD8 T cells
TIGIT TIGIT on T cells binds with the poliovirus receptor on the APCs and 
act as competitive antagonist to CD226 have suppressive effects
VISTA Expressed by both APCs and T cells plays a role in both Treg function 
and myeloid cell activation
Immunostimulatory 
checkpoints
ICOS It is a member of the CD28 family. It provides the second signal in 
immune activation by binding with B7H/B7RP-1.
CD40L CD40L interacts with CD40 receptor on T cells and function by 
promoting a proinflammatory immune response
OX40 OX40 downregulates Treg function by binding with the ligand 
OX40L.
It also induces the expression of pro-apoptotic proteins like BCL-2 and 
BCL-XL
Table 2. 
Immune checkpoints in immunotherapy.
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and is known to bind to poliovirus receptor on APCs or tumor cells. It is supposed 
to perform both direct and indirect immunosuppressive effects by competitively 
binding to NK and T cell receptors in place of CD226; it also leads to downstream 
inhibition of AKT signaling in T cells [14, 44]. In addition, TIGIT increases the 
suppressive activity and releases inhibitory cytokines by receptor binding of TIGIT 
on the APCs and Tregs [45]. Moreover, VISTA is expressed by both APCs and T cells 
play a role in both Treg function and myeloid cell activation [14].
On the contrary, other checkpoints like OX40, ICOS and CD40L are immunos-
timulatory checkpoints that function in the maintenance and activation of effector 
T cells. The expression of OX40 is induced at the time of T-cell activation leading to 
the expression of anti-apoptotic factors such as BCL-2 and BCL-XL that leads to the 
sustenance of T cells proliferation. It also acts as a co-stimulatory signal in tumor 
induction and is constitutively expressed on Tregs and OX40 also decreases the 
Treg function by binding to its receptor on Treg [46–48]. Furthermore, ICOS leads 
to the activation of second signal in immune activation by binding to B7H/B7RP-1 
[49]. Another immunostimulatory checkpoint CD40L interacts with CD40 on APCs 
induces via NF-ƙB signaling a proinflammatory immune response Table 2 [14].
The immunostimulatory checkpoints can be inhibited by therapeutic agents 
targeting recombinant ligand peptides, ligands expressing viral particles or ago-
nistic monoclonal antibody that is in contrast, to the inhibitory checkpoints where 
monoclonal antibodies inhibit the interaction between the respective ligand and 
receptors. Therefore, there is an emerging need to fully explore these biomarkers for 
better prognosis of patients using immunotherapy strategy [14].
7. Biomarkers in immunotherapy
Biomarkers are of significant importance in view that it predicts the clinical 
benefit to immunotherapy. Therefore, there is a need to bring into light several 
biomarkers in TNBC to distinguish that which patients is likely to get benefited 
from the ICIs or to build up certain therapies to overcome the hindrance in treat-
ing the respective malignancy. Until now PD-L1 was considered to be the major 
biomarker in TNBC. However, recent studies depicted that most of the mTNBC 
patients are PD-L1 negative arising the need to prospect into the immunotherapy 
field to find other novel biomarkers to get an insight into the patient responses to 
immunotherapy as a monotherapy or as a combinational therapy [50, 51]. Some 
of the biomarkers studied so far in TNBC include: TILs, TMB (tumor mutational 
burden), Gene signatures.
8. Tumor infiltrating lymphocytes as biomarkers (TILs)
Tumor infiltrating lymphocytes (TILs) have a predominant role in breast cancer 
as predictive and prognostic biomarker. It is present intratumorally and in adjacent 
stromal tissues. The increased presence of TILs in Breast cancer is associated with 
improved prognosis and overall survival in response to neoadjuvant chemotherapy 
[52, 53]. In a recent study higher number of TILs was in TNBC as compared to other 
breast cancer subtypes, therefore is associated with the possibility to show better 
responses to neoadjuvant and adjuvant chemotherapy with relapse free survival  
[54, 55]. The connection of TILs with anti-tumor immune response in TNBC patients 
also serves as a predictive biomarker, thereby making examination of immuno-
therapy in TNBC more interesting [14]. Furthermore, clinical trial KEYNOTE-173 
trial investigating pembrolizumab in combination with chemotherapy has shown 
Drug Repurposing - Molecular Aspects and Therapeutic Applications
10
promising results in the neoadjuvant setting of TNBC, as this trial demonstrated 
the presence of higher levels of TILs and higher PD-L1 expression resulting in a high 
combination score with increased overall response rates in TNBC patients [56].
9. Tumor mutational burden (TMB) as TNBC biomarker
TMB is defined as the measurement of non-synonymous mutations present in 
tumor cells. Here mutations lead to enhanced expression of neoantigens in terms 
of MHC I class antigens thereby increasing the visibility of cancer cells to T cells. 
However, limited data for TMB is reported while the frequencies of TMBs are found to 
be significantly higher in TNBC comparative to the other breast cancer sub types [57]. 
Therefore, the presence of TMB is linked with immunogenicity in several tumor types 
[58]. A recent study revealed no significant difference for breast cancer patients pre-
treated with ICIs (immune checkpoint inhibitors) in survival. Therefore, it is assumed 
that TMBs alone are not supposed to represent a sole predictor as biomarker evoking 
the need to enrich the available information regarding TNBC biomarkers [58, 59].
10. Gene signatures as biomarkers in TNBC
A number of multiple gene signatures in correlation with TILs have been stud-
ied as surrogates of breast cancer immunogenicity. According to immune-related 
gene expression profiling breast cancer consisted of four categories namely ICR1–4 
(immunologic constants of rejection) and these were seen to be associated with 
survival in a retrospective manner using in-silico analysis. Interestingly, the ICR4 
(Th1 helper phenotype) was linked with the upregulation of transcripts like PD-L1, 
IDO1, PD-1, FOXP3 and CTLA-4 that indicated a better survival among patients, in 
contrast a negative regulation was showed in disruptions induced by the presence 
of MAPK components linked with the ICR1, an unfavorable-immune response. A 
study on mouse models has shown an increased anti-tumor immune response in 
TNBC patients that was suggested to result by the inhibition of MEK, a molecule of 
MAPK pathway in combination with PD-1 inhibitor due to which the MHC I and 
PD-1 expression on Tumor cells increased resulting in apoptosis of cancer cells. 
Moreover, in TNBC a four gene-signature such as CXCL13, GBP1, SULT1E1 and HLF 
were shown to represent an upregulation of TILs and enhanced disease free survival 
among patients, however their predicting response with ICIs needs to be defined [58].
11. Importance of immune checkpoint inhibitors as monotherapy
Immunotherapy stimulates the immune system by active immunization with 
cancer vaccines or passive immunization with tumor-specific antibodies and 
immune modulators, such as immune-checkpoint inhibitors. Immune checkpoints 
are a complex group of adaptive immune system regulatory points that play roles 
in self-tolerance and antitumor immunity. These checkpoints regulate the immune 
response in either a negative or positive way, coordinating the magnitude and form 
of response. Immune checkpoint inhibitors (ICIs) are regarded as the emerging 
immunotherapy superheroes, allowing a patient’s self-immune cells to destroy 
tumors and remodeling cancer treatment in a board spectrum of cancers. The use of 
immune checkpoint inhibitors against programmed death receptor-1 (PD-1) or its 
ligand PD-L1 to treat a wide range of solid and hematologic tumors has dramatically 
altered the cancer treatment paradigm.
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11.1 PD-1 inhibitors
PD-1, also known as CD279, is a CD28 family member expressed on lymphoid 
cells such as T cells, B cells, and natural killer (NK) cells, as well as on myeloid 
cells [60]. The binding of PD-1 on T cells with the ligands PD-L1 or PD-L2 sup-
presses signals downstream of T-cell receptor activation in the context of antitumor 
immunity [61, 62]. The monoclonal antibody that target the programmed death-1 
receptor is Pembrolizumab, which is a humanized monoclonal antibody directed 
against PD-1.
11.2 Pembrolizumab
Pembrolizumab prevents immune-cell deactivation and inhibition by steri-
cally blocking the interaction of PD-1 and its ligands. Pembrolizumab was the first 
immune checkpoint inhibitor to be approved as a first-line treatment, as well as 
the first PD-1-targeted therapy. Pembrolizumab a dose of 10 mg/kg was adminis-
tered every two weeks to patients with previously treated, advanced TNBC in the 
KEYNOTE-012 trial, which showed efficacy and an adequate safety profile [63]. 
The overall response rate was 18.5 percent of the 27 patients who were assessed for 
antitumor activity, with 17.9 weeks an average response time (Table 3) [63]. The 
KEYNOTE-086 trial is presently examining the use of pembrolizumab (200 mg per 
3 weeks) in metastatic TNBC (NCT02447003). Cohorts A and B were presented 
in an oral session at the 2017 ASCO conference [64, 65]. Cohort A comprises of 
patients with TNBC who had advanced on at least one systemic treatment. Among 
the 170-patient cohort, 4.7% responded, and 7.6% accomplished disease control for 
24 weeks or longer, which included stable disease, partial response, and complete 
response [66]. In addition, 0.6% showed an absolute response to pembrolizumab 
monotherapy, and 27% had a decrease in the target lesion size after the first dose. 
The KEYNOTE-086 trial’s Cohort B included metastatic TNBC with PD-L1+ 
tumors, without having received some systematic treatment previously. 23% of the 
52 patients in this cohort showed an objective responses [64]. The use of pembro-
lizumab as a primary therapy and the inclusion of PD-L1+ tumors as a criterion for 
inclusion may have contributed to the increased response in cohort B, with only 58 
percent of the patients admitted had a cumulative PD-L1 positive composite score 
of >1 (Table 3) [64].
11.3 PD-L1 inhibitors
The monoclonal antibodies atezolizumab and avelumab target the PD-L1, a 
transmembrane protein found on tumor cells. Avelumab is a fully human IgG1 
MAB that binds to PD-L1, while as Atezolizumab is a humanized IgG1 isotype 
Agent Clinical trial id Cancer type Phase Recruitment status
Pembrolizumab NCT01848834 mTNBC Ib Completed
Pembrolizumab NCT02447003 mTNBC II Completed
Atezolizumab NCT01375842 mTNBC I Completed
Avelumab NCT01772004 mTNBC Ib Completed
Tremelimumab NCT02527434 mTNBC II Active, not recruiting
Table 3. 
Main monotherapy clinical trials of immune checkpoint inhibitors in mTNBC.
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monoclonal antibody that binds to PD-L1. The FDA has approved these PD-L1 
inhibitors for the treatment of other solid tumors, and they are currently being 
explored further for the treatment of TNBC.
11.4 Atezolizumab
The first PD-L1 inhibitor to receive FDA approval was atezolizumab. An open-
label, phase I dose-escalation analysis (NCT01375842) showed that Atezolizumab is 
safe in patients with locally advanced or metastatic solid tumors (Table 3). A cohort 
of 54 patients with mTNBC was evaluated for protection, and 21 patients were evalu-
ated for efficacy in this study. 69% of the patients in the protection cohort had PD-L1 
expression of at least ≥5%, and all of the patients in the efficacy cohort had PD-L1 
expression of at least ≥5%. The ORR for this study was 19%. There were three patients 
who had pseudoprogression, but their tumors gradually shrink. A total of 63% of 
patients experienced drug-related side effects, with 11% experiencing grade 3 toxicity. 
Pneumonitis of grade 4 was diagnosed in one of the patients. Fatigue (15%), fever 
(15%), and nausea (15%) were the most common drug-related side effects [67].
11.5 Avelumab
In a Phase 1b JAVELIN trial, a human anti-PD-L1 IgG1 mab, Avelumab, was 
tested in patients with MBC [68] (Table 3). A total of 168 MBC previously treated 
patients were treated with avelumab monotherapy, including 58 TNBC patients. 
The confirmed ORR for the whole population was 3%, with 1 CR (complete 
response) and 4 PRs (partial responses). The ORR for TNBC patients was 5.2 per-
cent. Furthermore, in both general population (16.7% vs. 1.6%) and in TNBC class 
(22.2% vs. 2.6%) patients with PD-L1 positive tumor-associated immune cells had a 
greater ORR than those with PD-L1 negative tumor-associated immune cells.
11.6 CTLA-4 inhibitors
CTLA-4 inhibits T-cell activation by interacting with its target ligand, CD80 
or CD86 [69, 70]. Monoclonal antibodies (mAbs) that block CTLA-4 have been 
demonstrated to augment T-cell activation and thereby enhance cancer cell death.
11.7 Tremelimumab
A phase II open-label trial (NCT02527434) is evaluating the efficacy of 
Tremelimumab, a CTLA-4 inhibitor, in patients with advanced solid tumors such as 
TNBC (Table 3). While on treatment with tremelimumab, if the patient’s develops 
progression in disease, they are given Durvalumab or a Durvalumab/Tremelimumab 
in combination. The objective response rate is the primary endpoint, with length of 
response, progression-free survival, and overall survival as secondary endpoints [71].
12. Drug repurposing an important aspect in immunotherapy regimen
Despite the success of disease diagnosis in modern era, the recent developments 
and discovery of new drug is laborious, inefficient, time consuming process and 
costly process [72, 73]. Not only that most drugs face high failure rates in clinical trials 
[74]. To overcome these problems in drug discovery a strategy namely drug repurpos-
ing (also called drug reprofiling or repurposing) came into existence which works by 
identifying existing drugs and using them for new purposes [75]. Several strategies 
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are being put to use in order to repurpose the existing drugs whether FDA approved 
or which are used under investigation. These include methods based on computa-
tional and non-computational strategies, also experimental based studies. However, 
the computational methods help in improved effectiveness in repurposing a drug. The 
computational methods help to select the effective candidate drugs before in-vitro-
experiments [76]. Drug repurposing in breast cancer is considered an old weapon 
for new war. The immunotherapy approach in combination with chemotherapy is 
considered an important modality in TNBC treatment. As already discussed due to 
escape mechanisms in immunotherapy it is being combined with chemotherapy that 
repurposing the old school drugs for instance some FDA  
approved drugs like Anthracyclines and taxanes. Also these drugs are being repur-
posed to modulate the immune system response for better clinical outcome  
[74, 77]. For instance, cyclophosphamide that is an alkylating chemotherapeutic 
agent having well-built immunosuppressive activity and acts via cytotoxic or through 
immune enhancing mechanisms. However due to its high toxicity effects low-dose 
cyclophosphamide has been combined with immunotherapy options like immune 
checkpoint inhibitors, immune therapeutic agents including vaccines as well and it 
been tested and has shown better results in animal models [77]. Accordingly in this 
chapter we have provided a detailed account for the combination of immunotherapy 
with chemotherapy as an effective mechanism for drug repurposing that is using the 
different strategies to modulate existing drugs for efficient use.
13. Checkpoint inhibitors in combination with chemotherapy
In the process of immunotherapy, a combination with chemotherapy may be 
synergistic. Chemotherapy has been demonstrated to promote tumor cell antigen 
release, prompt class I MHC molecules, neoantigens, and expression of PD-L1, and 
stimulate activation of dendritic cells, which could improve the immune response 
release after or in the course of Immune Checkpoint Inhibitor treatment [78–80]. 
Combination therapies of checkpoint inhibitors and chemotherapy have showed 
significant results in TNBC. Pembrolizumab’s safety profile and clinical efficacy 
have been examined in most of the analysis on inhibition of PD1 in TNBC. In 
highly positive PD-L1, untreated mTNBC patients who obtained pembrolizumab in 
conjunction with chemotherapy (PAX, nab-paclitaxel, carboplatin/gemcitabine), 
interim evaluation of the phase 3 KEYNOTE-355 (NCT02819518) trial shows a sub-
stantial increase in PFS (5.6 vs. 9.7 months) [81]. Pembrolizumab in combination 
with the microtubule inhibitor eribulin mesylate in the KEYNOTE-150/ENHANCE 
1 (NCT02513472) trial showed a 25.6 percent ORR with an average progression free 
survival of 4.1 months [82]. The TONIC trial (NCT02499367) phase 2 analyzed the 
effectiveness of PD1 with nivolumab in previously treated mTNBC patients. The 
ORR for nivolumab treatment followed by doxorubicin was 35%, compared to 23% 
for CIS and 17% for patients who did not receive prior chemotherapy, implying that 
chemotherapy would cause an inflamed tumor microenvironment [83]. For LA or 
mTNBC patients treated with atezolizumab in conjunction with nab-paclitaxel, the 
clinical study GP28328 (NCT01633970) phase 1b showed an ORR of 39.4% and an 
average PFS of 5.5 months (Table 4) [84].
The first randomized Phase 3 trial to show the effectiveness of atezolizumab 
in conjunction with nab-paclitaxel in metastatic TNBC patients which were not 
treated previously was IMpassion130 (NCT02425891) [80]. The FDA and the 
European Medicines Agency (EMA) approved atezolizumab in conjunction with 
nab-paclitaxel as a primary trearment for PD-L1-positive, uneradicably, locally 
advanced, or mTNBC in 2019. The IMpassion131 trial (NCT03125902) phase 3 will 
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assess the protection and effectiveness of atezolizumab in combination with PAX 
as a primary treatment in TNBC patients. The IMpassion 132 study (NCT03371017) 
examines the potential of previously treated, untreated, locally advanced and 
mTNBC patients who have not been eligible for the IMpassion130 trial may benefit 
from atezolizumab and chemotherapy (capecitabine, gemcitabine/carboplatin). 
Randomized study GeparNuevo (NCT02685059) phase 3 results demonstrated 
that durvalumab in conjunction with neoadjuvant chemotherapy based on taxane-
anthracycline provides clinical benefits in early TNBC from 44% to 53% of pCR 
(pathological complete response) [85]. A neo-adjuvant chemotherapy (paclitaxel 
plus carboplatin) NSABP B-59 (NCT03281954) phase 3 is currently being recruited 
with atezolizumab, followed by atezolizumab adjuvant and chemotherapy. The 
Impassion031 (NCT03197935) trial, which combines atezolizumab neoadjuvent 
with concurrent nab-paclitaxel and chemotherapy based on anthracyclines in 
patients with an early stage TNBC, recently published interim results. Patients who 
were given atezolizumab in combination with chemotherapy had a pCR rate of 
57.6%, compared to 41.1% in patients who obtained chemotherapy in combination 
with placebo [86].




NCT02819518 pembrolizumab + nab-paclitaxel 
or paclitaxel or gemcitabine/
carboplatin
Metastatic III Active, not 
recruiting
NCT02513472 pembrolizumab + eribulin 
mesylate
Metastatic Ib Active, not 
recruiting
NCT02499367 cyclophosphamide, cisplatin 
or doxorubicin followed by 
nivolumab
Metastatic II Active, not 
recruiting




NCT02425891 atezolizumab + nab-paclitaxel Metastatic III Active, not 
recruiting
NCT03125902 atezolizumab + paclitaxel Locally 
advanced, 
metastatic
III Active, not 
recruiting






NCT02685059 neoadjuvant durvalumab + nab-
paclitaxel + EC
early stage II Completed
NCT03281954 neoadjuvant atezolizumab + 
paclitaxel + carboplatin, followed 
by adjuvant atezolizumab + AC 
or EC
early stage III Recruiting
NCT03197935 neoadjuvant atezolizumab + nab-
paclitaxel, followed by AC
early stage III Active, not 
recruiting
AC- doxorubin + cyclophosphamide; EC- epirubicin + cyclophosphamide.
Table 4. 
Trials evaluating the use of immune checkpoint inhibitor in combination with chemotherapy.
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14.  Immune checkpoint blockade in combination with a targeted 
immunotherapy
14.1 Immune checkpoint inhibitors in combination with PARP inhibitors
Breast cancer patients with germline BRCA1 or BRCA2 mutations account for 
around 5% of all cases. While TNBC is the most common cancer with the muta-
tion in BRCA1 gene, cancers linked to the BRCA2 mutation can turn up in any 
subtype of breast cancer with the same frequency as sporadic subtypes. Breast 
cancers with BRCA1/2 mutations have a deficiency in homologous recombination 
repair, a DNA double-strand break repair mechanism, the defect which has a 
lethal synergy with single-strand DNA repair inhibition [87]. The poly(ADP-
ribose) polymerase (PARP) is involved in single-strand DNA repair, and PARP 
inhibitors have shown antitumor activity in patients with HER2-negative meta-
static breast cancer who have BRCA1/2 germline mutations. The use of immune 
checkpoint inhibitors in combination with PARPi in TNBC patients has the 
ability to cause a powerful immune response against tumors due to the infiltrat-
ing T cell activation followed by tumor antigen release via PARPi-induced cell 
death. Moreover, PARPi has been shown to increase the expression of PD-L1 in 
cell lines, supplying additional support for combining treatment with checkpoint 
inhibitors [88].
The TOPACIO (NCT02657889) trail found that a combination of pembroli-
zumab with the PARPi niraparib resulted in an ORR of 29% in mTNBC patients 
[89]. The ORR was higher than what has been identified in similar patient 
populations for anti-PD1 monotherapy [64]. In addition, various clinical trials 
evaluating the PD-L1 inhibition combination with PARP inhibitors in mTNBC 
have been planned, two phase II studies included the combination of the PARPi 
olaparib with durvalumab (NCT03167619 and NCT03801369) and a phase II 
trial of atezolizumab in combination with olaparib (NCT02849496). In addition, 
triplet PD-L1 inhibition therapies with PARPi and VEGF inhibitors are currently 
being developed. A phase I/II analysis (NCT02484404) in case of progressive or 
recurring solid tumor is looking at the combination of durvalumab in conjunc-
tion with olaparib and cediranib the VEGFR inhibitor. According to preliminary 
findings, the recommended dosage was bearable and resulted in clinical benefit 
rate of 67% in 9 women having recurring solid tumors, TNBC was one of them 
(Table 5) [90].
Trail id Intervention Phase Recruiting status
NCT02657889 pembrolizumab + niraparib II Active, not recruiting
NCT03167619 durvalumab + olaparib II Active, not recruiting
NCT03801369 durvalumab + olaparib II Recruiting
NCT02849496 atezolizumab + olaparib II Recruiting
NCT02484404 durvalumab + olaparib + VEGFRi I/II Recruiting
NCT02079636 Pembrolizumab+ Abemaciclib I Completed
NCT02322814 atezolizumab + taxanes + MEKi II Active, not recruiting
Table 5. 
Combinations of PD1/PD-L1 antibody-targeted therapy in TNBC.
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Figure 5. 
Diagram representing the targets of immune checkpoint inhibitors.
14.2  Immune checkpoint therapy and CDK4/6 (CDK4/6) inhibitors in 
combination therapy
In patients with ER-positive, HER2-negative metastatic breast cancers, phar-
macological inhibitors of CDK4/6 have demonstrated remarkable activity [91–93]. 
Inhibitors of CDK4/6 have been demonstrated to improve anti-tumor immune 
response in preclinical models by manipulating two main immune evasion mecha-
nisms in tumors [94–96]. First, CDK4/6 inhibitors elevate intracellular levels of 
double-stranded RNA by activating tumor cell expression of endogenous retroviral 
components. As a result, type III interferon synthesis is stimulated, which in turn 
improves tumor antigen presentation. Secondly, CDK4/6 inhibitors significantly 
reduce regulatory T-cell proliferation. Finally, these events facilitate tumor cell 
clearance by cytotoxic T cells, which can be intensified even further by the intro-
duction of an immune checkpoint inhibitor. Abemaciclib in conjunction with pem-
brolizumab was studied in patients with HER2-, HR+, MBC in a phase I trial (JPBJ, 
NCT02079636). The main objective of the study was to determine the combination 
therapy’s safety profile. A total of 28 patients were enrolled in the study. At the end 
of 24 weeks, four patients (14%) showed an analytical response. At the appropriate 
early time intervals in the MONARCH 1 analysis, this response was greater than the 
response shown by patients treated with abemaciclib monotherapy [97].
14.3 Combination of immune checkpoint inhibitors with MEK inhibitors
Suppression of the MAPK signaling pathway, which is frequently unregulated 
in TNBC and is correlated with enhanced proliferation of cells and shows resis-
tance towards apoptosis, is another approach for combining immune checkpoint 
inhibitors with targeted therapy [98]. In the phase 2 COLET (NCT02322814) trial, 
cobimetinib the MEK1/2 inhibitor was combined with atezolizumab and PAX/
nab-paclitaxel as a primary therapy in patients with LD or mTNBC. According 
to preliminary findings, paclitaxel in combination with nab-paclitaxel has a 34% 
ORR, while nab-paclitaxel has a 29% ORR [99]. Clinical studies of binimetinib the 
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MEK inhibitor in conjunction with pembrolizumab (NCT03106415) or avelumab 
(NCT03971409) in patients with LD or mTNBC are also underway (Figure 5).
14.4 Combination therapy: PD1/PD-L1 antibody and cancer vaccine
Cancer vaccines are a novel approach to cancer immunotherapy. These vaccines 
promote T cell priming and activation and strengthen immune recognition of can-
cer cells by presenting breast cancer peptides to T cells. Monovalent vaccines, which 
provide a single tumor-associated antigen (TAA) target for the immune system, 
and polyvalent peptide vaccines, which provide several TAA targets, are two types 
of cancer vaccines. Low response rates have hampered the application of peptide 
vaccines for the treatment of patients with metastatic cancer; although, making 
use of a multi-peptide vaccine strategy, the response rate in various cancer types 
has improved to 9.9%. [100, 101]. Furthermore, cancer vaccines in conjunction 
with immune checkpoint inhibitors can improve the vaccine’s anti-tumor immune 
response. In advanced TNBC, a few ongoing studies are looking into the effective-
ness of cancer vaccines in conjunction with pembrolizumab, making use of either 
the multipeptide vaccine PVX-410 (NCT03362060) or specific vaccines which 
target p53 (NCT02432963) or WT1 (NCT03761914). Furthermore, few clinical 
trials have been conducted to investigate the efficacy of durvalumab in combination 
with the multipeptide vaccine PVX-410 (NCT02826434) or with a neoantigen vac-
cine (NCT03606967, NCT03199040), as well as atezolizumab in combination with 
a neoantigen vaccine (NCT03289962) (Table 6).
15. Combining immunotherapy with epigenetics in cancer treatment
Immunotherapy arguably is one of the exciting new developments for the man-
agement of advanced human tumors, in particular the concept of immune check-
point blockade [102–104]. Antibodies targeting PD-1, CTLA-4 and PD-L1 show 
robust responses in treatment of melanoma, and in high grade tumors. Although, 
these recent advances are very exciting and promising, however majority of the 
tumor patients including TNBC patients show little or no response at all to immune 
checkpoint therapy alone [105, 106].
Therefore raising an apparent question as to whether immunotherapy could 
work in combination with other therapies like immune checkpoint targeting agents 
to enhance the clinical response and efficiency of various sub types of cancers. 
Nevertheless, various clinical trials as like previously discussed are evolving while 
keeping in control the related toxicities [107].
Trail id Intervention Phase Recruiting status
NCT03362060 pembrolizumab + PVX-410 I Active, not recruiting
NCT02432963 pembrolizumab + p53-specific vaccine I Active, not recruiting
NCT03761914 pembrolizumab + WT1-specific vaccine I/II Recruiting
NCT03606967 durvalumab + Nab-paclitaxel+ neoantigen 
vaccine
II Recruiting
NCT03199040 durvalumab + neoantigen DNA vaccine I Recruiting
NCT03289962 atezolizumab + neoantigen vaccine I Recruiting
Table 6. 
Current clinical trials for cancer vaccine and immunotherapy.
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Other combination strategies targeting immunotherapy in combination with 
chemotherapy as well targeted therapy approaches likely epigenetic therapy. As 
epigenetic therapy has been evidenced to strongly sensitize patients to immune 
checkpoint therapy.
16. Definition of epigenetic therapy
The term epigenetic therapy is now widely used, and involves use of drugs 
or other epigenome-influencing mechanisms for treatment of human disorders. 
Recent advances have delineated regulatory mechanisms of the cancer and normal 
epigenomes and the functional understanding of histone modifications, methyla-
tion patterns, and dynamics of nucleosomes [108, 109]. Recent studies in the field 
of cancer epigenetics have not only defined key targets for cancer management but 
also provided key insights in drug repurposing for modulating cancer epigenomes 
[110]. In epigenetic therapy, drugs target three specific protein categories (a) 
Writers, enzymes that establish epigenetic marks; (b) Readers, proteins that recog-
nize histone and may bring in other protein complexes to change gene expression; 
and (c) Erasers, enzymes that remove epigenetic marks [111]. Drugs that impede 
writers of DNA methylation, DNA methyltransferases (DNMT), and erasers (his-
tone deacetylases or HDAC) that regulate histone lysine acetylation are central to 
epigenetic therapy in cancer treatment. HDACs and DNMTs are mostly linked with 
transcriptional repression. Thus, inhibiting HDACs and DNMTs can upregulate 
expression of involved genes with many consequences for downstream pathways of 
this gene activation.
Cytidine analogues inhibit DNMTs by blocking their catalytic and likewise 
induces their degradation [112]. Also, the degradation of DNMTs can remove key 
scaffolding properties that may function for repression of transcription [113, 114]. 
Tumors show significant alterations in DNA methylation of cytosines at CpG 
dinucleotides such as loss of methylation at regions such as repetitive elements 
that must be silenced for genome stability and gain of methylation at the promoter 
regions of tumor suppressor and other genes [115]. Inhibitors targeting DNMTs 
promote reactivation of tumor suppressor, silenced by promoter DNA methyla-
tion [116]. DNA methylase inhibitors (DNMTi) showed augmented apoptosis, 
decreased cell cycle activity, and reduced stemness in a transient exposure to 
several cancer cells (Figure 6) [117]. DNMTis such as 5-azacytidine and 5-aza-
20-deoxycytidine showed robust efficacy in treatment of hematological disorders 
and has been approved by FDA for the treatment of myelodysplastic syndrome 
(MDS) [118]. Several clinical studies are undergoing presently to study the effect of 
epigenetic therapy in cancer treatment Table 7.
Histone modifications by acetylation plays a central role in epigenetic gene 
regulation by altering the condensation status of chromatin, modulating the 
accessibility of transcription factors to target DNA sites. Histone acetyltransferases 
(HAT) and HDACs maintain the acetylation state of histones of nucleosomes. 
Inhibitors targeting HDACs known as (HDACi) are presently approved for the 
treatment of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma 
(CTCL), although it is yet to be known as why these two cancers are highly sensitive 
towards HDACi [119, 120]. Also, it has been observed that HDACi show dependency 
of, compound, dose and pleotropic characteristics. Many of the HDACi directly 
affect acetylation of histone proteins and modulate epigenetic changes while some 
affect acetylation of non-histone or cytoplasmic proteins [121]. Besides, it has been 
observed that transient exposure of tumor cells to low doses of DNMTs, followed by 
HDACi treatment increases gene expression of hypermethylated genes.
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17. Connecting epigenetic modulation with immunotherapy
Over In the past two decades, the FDA approval of various DNA methyltrans-
ferase inhibitors, collectively called DNA HMAs, and histone deacetylase inhibi-
tors (HDACi) has brought epigenetic therapy to the forefront of cancer therapies. 
However, the benefits of epigenetic therapy are mainly restricted to the treatment 
of hematological malignancies. Thus, combination strategies with standard che-
motherapy and targeted therapy approaches can be considered. A recent study 
involving advanced NSCLC patients revealed that patients after receiving low-dose 
epigenetic therapy entered a trial for immune checkpoint therapy. Approximately 
20% of the patients responded to the immune checkpoint therapy alone, passing 
24 weeks without progression, with most achieving high-grade RECIST criteria 
responses [122]. This is an astounding result for immunotherapy in NSCLC. All 5 
Figure 6. 
Flowchart representing the overall effects of epigenetic therapy.
Epigenetic inhibitor Target Type of cancer
Entinostat HDAC1/HDAC3 Recurrent or refractory solid 
tumors
KA2507 HDAC6 Solid tumors
Tazemetostat EZH2 Advanced solid Tumors
AZD5153 BRD4 Advanced solid tumors and 
lymphomas
Triple: Entinostat, Nivolumab and 
Ipilimumab
HDAC/ICB Locally advanced or metastatic
HER2-negative breast cancer
Entinostat plus Pembrolizumab HDAC/ICB Advanced solid Tumors
CC-486 plus Durvalumab HMA/ICB Colorectal, ovarian, and breast 
tumors
CPI-1205 plus Ipilimumab EZH2/ICB Advanced solid tumors
Table 7. 
Clinical trials for epigenetic inhibitors.
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patients who had received the prior epigenetic therapy passed the 24-week point 
without progression with subsequent immune checkpoint therapy and three of 
these developed high-grade partial RECIST criteria responses that have all been 
durable over 2.5 years [123, 124]. Moreover, findings to date, support the hypothesis 
that there may be extraordinary potential for combined epigenetic and immuno-
therapy to increase the frequency of durable responses for immune checkpoint 
therapy in not only NSCLC but also other common tumor types.
18.  Epigenetic therapy drugs boost immune attraction properties of 
epithelial cancer cells
Immunotherapy has presently become a remarkable tool to employ immune 
cells in tumor management. Blocking immune checkpoints to stimulate and retore 
immune response in the tumor immune suppressive microenvironment has showed 
robust clinical response. However, several patients tend to remain unresponsive 
towards immune checkpoints blockades. Epigenetic therapy using DNMTis and 
HDACis have showed potential in immune modulation properties of tumor cells 
and immune cells, thereby suggesting a rationale for integrating epigenetic with 
immunotherapy.
It is well known that cytotoxic T cells (Tc) are requisite for an anti-cancer 
immune response and immune check point blockade. This mechanism relies on 
antigen presenting cells and the quantity of antigens presented to Tc cells. Also, 
tumors with high mutations show robust response to immune check point blockade 
due to high presence of neo-antigens presented to Tc cells [125, 126]. Several stud-
ies demonstrate that high immunogenicity is followed by exposure to epigenetic 
therapy. DNTMis have been found to upregulate and augment expression of cancer 
testis antigens (CTAs) such as MAGE-A1 and NY-ESO-1 [127]. Besides, exposure to 
epigenetic therapy viz. HDACis and DNMTis also upregulated antigen presenting 
and processing related genes such as b2-microglobulin, Human leukocyte antigen 
(HLA)-class I genes, and TAP1 in solid tumors [128, 129]. Furthermore, it was 
revealed that HDAC inhibitors stimulate human endogenous retroviruses (HERVs) 
reactivation, which induce activation of pattern recognition receptors and a type 
I/III interferon response thereby enhancing antigen presentation to Tc cells [129, 
130]. Together, these results paint the picture that epigenetic therapy using HDACis 
and DNMTis augment presentation of CTA and HERV-derived antigens, thus 
enhancing immune response in low mutation therapy [131]. In AML patients, epi-
genetic therapy with DNMTis promoted robust T cell mediated immune response 
by reactivation of CTAs [132]. The host immune system recognizes the CTAs with 
high affinity, they represent good candidates for immunotherapy, including vac-
cines. There is thus great potential for DNMT inhibitor treatment to upregulate 
CTAs on tumors, facilitating targeting by the host immune system [133]. Guo et al. 
demonstrated that exposure of 4T1 mammary carcinoma cells in syngeneic mice to 
DNMTi 5-aza-2-deoxycytidine induced demethylation and upregulation of CTA 
P1A. Also, the upregulated P1A was targeted by P1A–specific T cells, and combined 
therapy with 5- aza-20-deoxycytidine and adoptive transfer of these T cells signifi-
cantly reduced lung metastases in this mouse model [134].
Additionally, synergistic relation was observed in pre-clinical models of diffuse 
large B cell lymphomas for combinatorial exposure to DNMTis and HDACis [135]. 
Increasing evidence suggests that tumors possess variable numbers of infiltrated 
immune cells and the quantity, type, and location of infiltration can help in predict-
ing response to immune check point blockade [36, 136]. It is now well established 
that epigenetic therapy with modulates directly infiltration of immune cells in 
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tumor stroma. DNMTi treatment in addition to inhibiting tumor progression, 
increased infiltration of CD8+ T cell infiltration, and natural killer (NK) cells and 
reduced infiltration of immune-suppressive cells [131, 137]. Also, HDACis treat-
ment in combination with DNMTis activates chemokine signaling networks and 
augments infiltration of cytotoxic T cells [138]. In preclinical studies, treatment 
with romidepsin, the pan-HDAC inhibitor, augmented expression of chemokines by 
tumor cells which elevated infiltration of T cells into the tumor stroma and reduced 
tumor growth by robust immune response [139].
Accumulating evidence from preclinical models of diverse solid tumors viz. 
breast, melanoma and colorectal cancer, revealed that combining immune check 
point inhibitors such as anti-CTLA4 or anti-PD1 with epigenetic therapy (DNMTis 
and HDACis) augmented antitumor response and reduced tumor growth and 
response to immunotherapy than using monotherapy of either agent [122, 136]. 
Also, combinational treatment with DNMTis and anti-CTLA4 antibody enhanced 
chemokine expression and increased survival of mice with orthotopic or subcuta-
neous tumors [137].
Together, these results paint the picture that combining immunotherapy 
with combinational therapy, greatly enhances antitumor immune responses, by 
augmented expression of chemokines and these act in a synergistic manner. Also, 
multiple clinical trials are currently testing the combination of DNMTi or HDACi 
with various immune check point inhibitors (Table 7).
19.  Integrating immunotherapy with oncolytic viruses for cancer 
treatment
The antitumor activity of oncolytic viruses involves multiple mechanisms that 
encompass the natural interactions between viruses, tumor cells and the immune 
system [140]. During the last decade oncolytic viruses are becoming an effective 
means in cancer treatment. Viruses have developed sophisticated means to escape 
immune surveillance and which can be manipulated for therapeutic purposes to 
stimulate anti-cancer immune response. Likewise, nearby infusion of oncolytic 
virus into a tumor site can incite an abscopal impact, in which distant, uninfected 
tumors additionally go through insusceptible immune rejection [141]. This abscopal 
effect is caused by oncolytic viruses’ sequential activity, multiply in cancer cells and 
then progresses to activation of immunogenic cell death, which results in the release 
of antigens and danger factors, which then enhance both innate and adaptive anti-
tumor immune responses. Furthermore, oncolytic viruses can be genetically modi-
fied to express therapeutic genes, which can improve antitumor activity even more. 
In the absence of viral replication, viral encoded gene expression allows immune 
regulation against tumors while restricting the antiviral immune response [142]. 
This points out, oncolytic viruses are highly adaptable agents that offer a critical 
‘on’ switch that enhances the migration of tumor infiltrating lymphocytes into 
the tumor stroma, and this can be exploited to improve antigen-specific immune 
responses as part of combo-immuno therapies.
20. Characteristics of oncolytic viruses
Viruses are microscopic particles that selectively replicate in the interior milieu 
of host cells, and inflammation and underlying pathogenicity can be associated 
with viral infection [143]. During the last decades, viruses have been employed 
in delivery of therapeutic genes for the treatment of metabolic and degenerative 
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illnesses, immunization against infectious diseases, and as oncolytic agents for 
cancer therapy [140].
The genome, which is either single-stranded or double-stranded RNA or DNA; 
the capsid, which is a protein coat that covers the genetic material; and the capsid, 
which is a protein coat that covers the genetic material, also in certain viruses, the 
lipidic envelope which surrounds the capsid and may enhance virus adhesion to 
host cell membranes, so increasing viral penetration, are the three major struc-
tural parts of most viruses. Oncolytic viruses have been developed over the last 
decade using both DNA and RNA viruses. DNA viruses offer several advantages: 
their huge genomes can be altered without interfering with viral replication; big 
eukaryotic transgenes may be incorporated by DNA viruses to boost therapeutic 
effectiveness or immunological regulation; DNA viruses express high fidelity DNA 
polymerases, assuring viral genome integrity and effective replication; and there 
is little, if any, nuclear integration of DNA viruses Table 8 [144]. RNA viruses 
offer additional advantages: because they are smaller than DNA viruses, they can 
pass the blood–brain barrier, allowing tumors in the central nervous system to be 
targeted [145]. Despite the fact that their short genome restricts their capacity to 
encode big transgenes, because pre-existing tolerance to certain RNA viruses is 
poor in humans, viruses are more suited for systemic distribution, at least for the 
brief period before antiviral immunity is generated. Furthermore, the detection of 
viral double-stranded RNA by protein kinase R (PKR) that happens in normal cells 
may not occur in tumor cells, which often have lower levels and phosphorylation of 
PKR [146, 147]. Many aspects influence the selection of oncolytic viruses for tumor 
immunotherapy, in particular high pathogenicity, immunogenicity, cancer tropism, 
the potential to encode therapeutic transgenes, feasible viral concentration during 
synthesis, and durability. The active phase of viral infection and reproduction in 
host cells is described by the lytic virus life cycle [148]. Attachment, penetration 
and uncoating, synthesis, assembly, and release are the five different phases of the 
viral life cycle, which may be managed by genetic modification of the viral genome 
and can serve as a physiologically realistic strategy for selectively targeting tumor 
Adenovirus Coxsackie virus Maraba virus Pox virus
Genome dsDNA ssRNA ss (−) RNA dsDNA
Genome size Moderate 
(32 kb)

























Moderate Low Very low High
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immunogenicity




Very limited Moderate Limited Very limited
Table 8. 
Characteristics of oncolytic virus.
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cells for infection and viral replication. Viruses also display pathogenicity and 
immunogenicity, which vary depending on viral species, dosage, mode of admin-
istration, pre-existing host immunity, and other variables, and are characteristics 
that can produce effective antitumor immunity.
21. Anti-tumor activity of oncolytic viruses
Considering they influence multiple crucial phases in the cancer–immunity pro-
cess, oncolytic viruses offer several benefits as cancer treatment agents [149]. These 
features include preferential replication in tumor cells, stimulation of immunogenic 
cell death and release of soluble antigens and danger signals, induction of innate 
immune responses by recruitment of immature dendritic cells (DCs) and innate 
lymphoid cells, correction of antigen processing and presentation abnormalities, 
and activation of adaptive immunological responses. Although the molecular and 
cellular intricacies of how oncolytic viruses correct these processes are not entirely 
known, advances in the generation of antitumor immunity employing oncolytic 
viruses are being achieved, and insights into rational combination therapy based on 
oncolytic viruses are being explored.
22.  Combing oncolytic virus treatment with immune check point 
blockade
Immune check point blockade therapy (ICB) is extensively in cancer treatment, 
and long-term clinical outcomes are promising. Clinical responses are associated 
with pre-existing antitumor immune responses, such as an increased number of 
TILs, a high mutation load, and the formation of a diverse neoantigen repertoire 
[150, 151]. Combination therapy utilizing ICB and oncolytic viruses are appealing 
because the oncolytic virus can drive recruitment of TILs into immune-deficient 
tumors and prompt the production of soluble tumor antigens, danger signals, and 
pro-inflammatory cytokines, which can improve T cell recruitment and boost 
immune cell activation. Viral infection also raises the expression of CTLA4, PDL1, 
and other immunological checkpoint molecules, which would normally inhibit T 
cell activation (and so antitumor immunity), but also makes tumors more suscep-
tible to ICB (Figure 7) [152, 153]. Preclinical research with a B16–F10 melanoma 
indicated that localized injection of tumors with oncolytic Newcastle disease virus 
caused infiltration of tumor-specific CD4+ T cells and CD8+ T cells into both the 
injected tumor and distant tumors, as well as improved tumor susceptibility to 
systemic CTLA4 inhibition 18. An oncolytic virus Maraba demonstrated thera-
peutic potential as a neoadjuvant in a preclinical model of triple-negative breast 
cancer and sensitized previously refractory tumors to ICB [154]. Several additional 
oncolytic viruses, including B18R-deficient vaccinia virus and vesicular stomatitis 
virus expressing a library of melanoma antigens (VSV- ASMEL), also shown 
substantial (P 0.05) therapeutic effect when used in tandem with ICB [155, 156]. 
Administration of T- VEC intratumorally, followed by anti-CTLA4 antibody (ipili-
mumab) treatment via intravenous injection, demonstrated an object response rate 
of 50%, with 44% of patients showing robust responses lasting more than 6 months 
in a phase Ib clinical trial. Also, no dose limiting toxicities were observed in the 
patients [157]. Additionally, a recent study reported that treatment with oncolytic 
poxvirus CF33-hNIS-ΔF14.5 modulates tumor microenvironment in TNBC model, 
and increases the response of tumor cells towards anti-PD-L1 antibody. Tumor 
microenvironment is one of the central plays in tumor growth, metastasis and 
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development of resistance. Further in vivo and in vitro analysis revealed that infec-
tion with the virus stimulated expression of PD-L1 in TNBC cells. Also, exposure of 
mice model of TNBC to oncolytic poxvirus CF33-hNIS-ΔF14.5 enhanced infiltra-
tion of CD8+ T cells and increased expression of proinflammatory cytokines IFNγ 
and IL-6 by tumor cells. Combinational treatment with oncolytic poxvirus CF33-
hNIS-ΔF14.5 and anti-PD-L1 antibody augmented TME modulation and induced 
50% tumor regression in mice models. Administration of these as single agents 
failed to inhibit tumor growth. Besides, it was also observed that the recovered mice 
with combinational treatment did not develop tumor after re-challenge with the 
same cancer cells suggesting that they developed immunity against those cancer 
cells [158, 159].
Taken together, studies demonstrate that oncolytic virus treatment positively 
induces tumor immune microenvironment modulation in triple-negative breast 
cancer model making them responsive to the immune checkpoint inhibitors and 
hence warrants further studies to determine the clinical applicability of this combi-
nation approach.
23. Summary
1. Chemotherapy lacks the success in treating malignant tumors like TNBC as it 
lacks specificity and can act on normal healthy cells causing secondary diseases 
in patients.
2. Furthermore, immunotherapy have shown downfall in its efficacy due to 
the major problem of escape of tumor cells from the immune response 
against them.
3. Therefore, drug repurposing a strategy commonly used to reprofile or re-
purpose the existing chemotherapeutic drug has shown promising effects in 
targeting various diseases including malignant tumors.
Figure 7. 
Represents the role of oncolytic virus in immunotherapy.
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4. Drug repurposing is mainly done by using both computational and non-com-
putational methods including target-based computational studies and in vitro 
based experimental studies
5. These methods permit us to select an existing drug whether FDA approved or 
drugs that are under investigational studies before in vitro studies thus reduc-
ing time consumption and proving cost effective.
6. Because most chemotherapeutic drugs are toxic in nature and lack target speci-
ficity as well, therefore by using drug repurposing approach we can combine 
the chemotherapeutic drugs with target specific immunotherapeutic options to 
make them effective.
7. Therefore, chemotherapeutic drugs can be combined with immune checkpoint 
inhibitors, PD-1/PD-L1 antibody and vaccines to provide promising results in 
anti-tumor response
8. Various enlisted clinical trials have shown promising results in combining 
chemotherapy with immunotherapy.
24. Future perspective
TNBC is the most aggressive, lethal and complex subtype of breast cancer. What 
makes it more aggressive is the lack of targeted therapies leaving chemotherapy as 
the main treatment option available. However, chemotherapy itself mostly lacks 
target specificity and can harm normal healthy cells of an individual. Moreover, 
another treatment option that is immunotherapy also faces some problems showing 
inefficacy due to escape of tumor cells from immune surveillance. Nevertheless, 
a strategy known as drug repurposing has shown to be a promising strategy to 
overcome the inefficacy of available treatment options. In drug repurposing, an 
existing chemotherapeutic drug can be repurposed to modulate its efficacy. In this 
chapter, we have focused primarily on repurposing the available drugs whether 
PARP inhibitors or MEK inhibitors, vaccines including the ones under clinical trials 
as well by combining them with other available immunotherapeutic options like 
immune checkpoint inhibitors, PD-1/PD-L1 antibodies etc. Also the currently used 
epigenetic therapy drugs also are known to show significant efficacy in modulating 
immunotherapy responses in patients suffering from cancers especially TNBC. 
From our point of view combining drugs with other target specific drugs like drugs 
targeting immune system components provides a significant insight as it repurposes 
the drug whether chemotherapeutic or epigenetic drug making it target specific.
Drug Repurposing - Molecular Aspects and Therapeutic Applications
26
Author details
Hina Qayoom, Umar Mehraj, Shariqa Aisha, Shazia Sofi and Manzoor Ahmad Mir*
Department of Bioresources, School of Biological Sciences, University of Kashmir, 
Srinagar, J&K, India
*Address all correspondence to: drmanzoor@kashmiruniversity.ac.in
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
27
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
DOI: http://dx.doi.org/10.5772/intechopen.100183
References
[1] Garrido-Castro AC, Lin NU, 
Polyak K. Insights into molecular 
classifications of triple-negative breast 
cancer: improving patient selection for 
treatment. Cancer discovery 
2019;9:176-98.
[2] Topalian SL, Hodi FS, Brahmer JR, 
Gettinger SN, Smith DC, 
McDermott DF, et al. Safety, activity, 
and immune correlates of anti–PD-1 
antibody in cancer. New England 
Journal of Medicine 2012;366:2443-54.
[3] Denkert C, von Minckwitz G, 
Darb-Esfahani S, Lederer B, 
Heppner BI, Weber KE, et al. Tumour-
infiltrating lymphocytes and prognosis 
in different subtypes of breast cancer: a 
pooled analysis of 3771 patients treated 
with neoadjuvant therapy. The lancet 
oncology 2018;19:40-50.
[4] Fehrenbacher L, Spira A, 
Ballinger M, Kowanetz M, 
Vansteenkiste J, Mazieres J, et al. 
Atezolizumab versus docetaxel for 
patients with previously treated non-
small-cell lung cancer (POPLAR): a 
multicentre, open-label, phase 2 
randomised controlled trial. The Lancet 
2016;387:1837-46.
[5] Loi S, Drubay D, Adams S, 
Pruneri G, Francis PA, Lacroix-Triki M, 
et al. Tumor-infiltrating lymphocytes 
and prognosis: a pooled individual 
patient analysis of early-stage triple-
negative breast cancers. Journal of 
clinical oncology 2019;37:559.
[6] Mittendorf EA, Philips AV, 
Meric-Bernstam F, Qiao N, Wu Y, 
Harrington S, et al. PD-L1 expression in 
triple-negative breast cancer. Cancer 
immunology research 2014;2:361-70.
[7] Gatalica Z, Snyder C, Maney T, 
Ghazalpour A, Holterman DA, Xiao N, 
et al. Programmed cell death 1 (PD-1) 
and its ligand (PD-L1) in common 
cancers and their correlation with 
molecular cancer type. Cancer 
Epidemiology and Prevention 
Biomarkers 2014;23:2965-70.
[8] Luen S, Virassamy B, Savas P, 
Salgado R, Loi S. The genomic landscape 
of breast cancer and its interaction with 
host immunity. The Breast 
2016;29:241-50.
[9] Schumacher TN, Schreiber RD. 
Neoantigens in cancer immunotherapy. 
Science 2015;348:69-74.
[10] Yarchoan M, Johnson Iii BA, 
Lutz ER, Laheru DA, Jaffee EM. 
Targeting neoantigens to augment 
antitumour immunity. Nature Reviews 
Cancer 2017;17:209.
[11] Lehmann BD, Bauer JA, Chen X, 
Sanders ME, Chakravarthy AB, Shyr Y, 
et al. Identification of human triple-
negative breast cancer subtypes and 
preclinical models for selection of 
targeted therapies. The Journal of 
clinical investigation 2011;121:2750-67.
[12] Hanahan D, Weinberg RA. 
Hallmarks of cancer: the next 
generation. cell 2011;144:646-74.
[13] de Visser KE, Coussens LM. The 
inflammatory tumor microenvironment 
and its impact on cancer development. 
Infection and Inflammation: Impacts on 
Oncogenesis 2006;13:118-37.
[14] Borcherding N, Kolb R, 
Gullicksrud J, Vikas P, Zhu Y, Zhang W. 
Keeping tumors in check: a mechanistic 
review of clinical response and 
resistance to immune checkpoint 
blockade in cancer. Journal of molecular 
biology 2018;430:2014-29.
[15] Hagerling C, Casbon A-J, Werb Z. 
Balancing the innate immune system in 
tumor development. Trends in cell 
biology 2015;25:214-20.
Drug Repurposing - Molecular Aspects and Therapeutic Applications
28
[16] Twyman-Saint Victor C, Rech AJ, 
Maity A, Rengan R, Pauken KE, 
Stelekati E, et al. Radiation and dual 
checkpoint blockade activate non-
redundant immune mechanisms in 
cancer. Nature 2015;520:373-7.
[17] Sharabi AB, Lim M, DeWeese TL, 
Drake CG. Radiation and checkpoint 
blockade immunotherapy: 
radiosensitisation and potential 
mechanisms of synergy. The lancet 
oncology 2015;16:e498-e509.
[18] Takahashi Y, Yasui T, Tamari K, 
Minami K, Otani K, Isohashi F, et al. 
Radiation enhanced the local and 
distant anti-tumor efficacy in dual 
immune checkpoint blockade therapy in 
osteosarcoma. PLoS One 
2017;12:e0189697.
[19] Langer CJ, Gadgeel SM, Borghaei H, 
Papadimitrakopoulou VA, Patnaik A, 
Powell SF, et al. Carboplatin and 
pemetrexed with or without 
pembrolizumab for advanced, non-
squamous non-small-cell lung cancer: a 
randomised, phase 2 cohort of the 
open-label KEYNOTE-021 study. The 
lancet oncology 2016;17:1497-508.
[20] Gandhi L, Rodríguez-Abreu D, 
Gadgeel S, Esteban E, Felip E, De 
Angelis F, et al. Pembrolizumab plus 
chemotherapy in metastatic non–small-
cell lung cancer. New England journal of 
medicine 2018;378:2078-92.
[21] Gardner AB, Lee SKC, Woods EC, 
Acharya AP. Biomaterials-based 
modulation of the immune system. 
BioMed research international 
2013;2013.
[22] Hontscha C, Borck Y, Zhou H-w, 
Messmer D, Schmidt-Wolf IGH. Clinical 
trials on CIK cells: first report of the 
international registry on CIK cells 
(IRCC). Journal of cancer research and 
clinical oncology 2011;137:305-10.
[23] Salmaninejad A, Valilou SF, 
Shabgah AG, Aslani S, Alimardani M, 
Pasdar A, et al. PD-1/PD-L1 pathway: 
Basic biology and role in cancer 
immunotherapy. Journal of cellular 
physiology 2019;234:16824-37.
[24] Ljunggren HG, Jonsson R, 
Höglund P. Seminal immunologic 
discoveries with direct clinical 
implications: The 2018 Nobel Prize in 
Physiology or Medicine honours 
discoveries in cancer immunotherapy. 
Wiley Online Library; 2018.
[25] Messenheimer DJ, Jensen SM, 
Afentoulis ME, Wegmann KW, Feng Z, 
Friedman DJ, et al. Timing of PD-1 
blockade is critical to effective 
combination immunotherapy with 
anti-OX40. Clinical Cancer Research 
2017;23:6165-77.
[26] Iwai Y, Hamanishi J, Chamoto K, 
Honjo T. Cancer immunotherapies 
targeting the PD-1 signaling pathway. 
Journal of biomedical science 
2017;24:1-11.
[27] Parkhurst MR, Riley JP, Dudley ME, 
Rosenberg SA. Adoptive transfer of 
autologous natural killer cells leads to 
high levels of circulating natural killer 
cells but does not mediate tumor 
regression. Clinical Cancer Research 
2011;17:6287-97.
[28] Yu R, Yang B, Chi X, Cai L, Liu C, 
Yang L, et al. Efficacy of cytokine-
induced killer cell infusion as an 
adjuvant immunotherapy for 
hepatocellular carcinoma: a systematic 
review and meta-analysis. Drug design, 
development and therapy 2017;11:851.
[29] Schmidt-Wolf IG, Lefterova P, 
Mehta BA, Fernandez LP, Huhn D, 
Blume KG, et al. Phenotypic 
characterization and identification of 
effector cells involved in tumor cell 
recognition of cytokine-induced killer 
cells. Experimental hematology 
1993;21:1673-9.
[30] Li M, Wang Y, Wei F, An X, 
Zhang N, Cao S, et al. Efficiency of 
29
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
DOI: http://dx.doi.org/10.5772/intechopen.100183
cytokine-induced killer cells in 
combination with chemotherapy for 
triple-negative breast cancer. Journal of 
breast cancer 2018;21:150.
[31] Pardoll DM. The blockade of 
immune checkpoints in cancer 
immunotherapy. Nature Reviews Cancer 
2012;12:252-64.
[32] Ishida Y, Agata Y, Shibahara K, 
Honjo T. Induced expression of PD-1, a 
novel member of the immunoglobulin 
gene superfamily, upon programmed 
cell death. The EMBO journal 
1992;11:3887-95.
[33] Neel BG, Gu H, Pao L. The ‘Shp'ing 
news: SH2 domain-containing tyrosine 
phosphatases in cell signaling. Trends in 
biochemical sciences 2003;28:284-93.
[34] Ahmadzadeh M, Johnson LA, 
Heemskerk B, Wunderlich JR, 
Dudley ME, White DE, et al. Tumor 
antigen–specific CD8 T cells infiltrating 
the tumor express high levels of PD-1 
and are functionally impaired. Blood 
2009;114:1537-44.
[35] Staron MM, Gray SM, Marshall HD, 
Parish IA, Chen JH, Perry CJ, et al. The 
transcription factor FoxO1 sustains 
expression of the inhibitory receptor 
PD-1 and survival of antiviral CD8+ T 
cells during chronic infection. Immunity 
2014;41:802-14.
[36] Youngblood B, Oestreich KJ, Ha S-J, 
Duraiswamy J, Akondy RS, West EE, et 
al. Chronic virus infection enforces 
demethylation of the locus that encodes 
PD-1 in antigen-specific CD8+ T cells. 
Immunity 2011;35:400-12.
[37] Xiao G, Deng A, Liu H, Ge G, Liu X. 
Activator protein 1 suppresses 
antitumor T-cell function via the 
induction of programmed death 1. 
Proceedings of the National Academy of 
Sciences 2012;109:15419-24.
[38] Salmaninejad A, Khoramshahi V, 
Azani A, Soltaninejad E, Aslani S, 
Zamani MR, et al. PD-1 and cancer: 
molecular mechanisms and 
polymorphisms. Immunogenetics 
2018;70:73-86.
[39] Vikas P, Borcherding N, Zhang W. 
The clinical promise of immunotherapy 
in triple-negative breast cancer. Cancer 
management and research 2018;10:6823.
[40] Piechocki MP, Wu GS, Jones RF, 
Jacob JB, Gibson H, Ethier SP, et al. 
Induction of proapoptotic antibodies to 
triple-negative breast cancer by 
vaccination with TRAIL death receptor 
DR5 DNA. International journal of 
cancer 2012;131:2562-72.
[41] Han Y, Liu D, Li L. PD-1/PD-L1 
pathway: current researches in cancer. 
American journal of cancer research 
2020;10:727.
[42] Linsley PS, Bradshaw J, Greene J, 
Peach R, Bennett KL, Mittler RS. 
Intracellular trafficking of CTLA-4 and 
focal localization towards sites of TCR 
engagement. Immunity 1996;4:535-43.
[43] Buchbinder EI, Desai A. CTLA-4 
and PD-1 pathways: similarities, 
differences, and implications of their 
inhibition. American journal of clinical 
oncology 2016;39:98.
[44] Li M, Xia P, Du Y, Liu S, Huang G, 
Chen J, et al. T-cell immunoglobulin and 
ITIM domain (TIGIT) receptor/
poliovirus receptor (PVR) ligand 
engagement suppresses interferon-γ 
production of natural killer cells via 
β-arrestin 2-mediated negative 
signaling. Journal of Biological 
Chemistry 2014;289:17647-57.
[45] Manieri NA, Chiang EY, Grogan JL. 
TIGIT: a key inhibitor of the cancer 
immunity cycle. Trends in immunology 
2017;38:20-8.
[46] Linch SN, McNamara MJ, 
Redmond WL. OX40 agonists and 
combination immunotherapy: putting 
Drug Repurposing - Molecular Aspects and Therapeutic Applications
30
the pedal to the metal. Frontiers in 
oncology 2015;5:34.
[47] Rogers PR, Song J, Gramaglia I, 
Killeen N, Croft M. OX40 promotes 
Bcl-xL and Bcl-2 expression and is 
essential for long-term survival of CD4 
T cells. Immunity 2001;15:445-55.
[48] Piconese S, Valzasina B, 
Colombo MP. OX40 triggering blocks 
suppression by regulatory T cells and 
facilitates tumor rejection. The Journal 
of experimental medicine 
2008;205:825-39.
[49] Dong C, Juedes AE, Temann U-A, 
Shresta S, Allison JP, Ruddle NH, et al. 
ICOS co-stimulatory receptor is 
essential for T-cell activation and 
function. Nature 2001;409:97-101.
[50] Schmid P, Park YH, Ferreira M, 
editors. Keynote-522 study of 
pembrolizumab+ chemotherapy vs 
placebo+ chemotherapy as neoadjuvant 
treatment, followed by pembrolizumab 
vs placebo as adjuvant treatment of 
early triple-negative breast cancer: 
pathologic complete response in key 
subgroups2019.
[51] Rugo HS, Loi S, Adams S, Schmid P, 
Schneeweiss A, Barrios CH, et al. 
Performance of PD-L1 
immunohistochemistry (IHC) assays in 
unresectable locally advanced or 
metastatic triple-negative breast cancer 
(mTNBC): post-hoc analysis of 
IMpassion130. Annals of Oncology 
2019;30:v858-v9.
[52] Loi S. Tumor-infiltrating 
lymphocytes, breast cancer subtypes 
and therapeutic efficacy. 
Oncoimmunology 2013;2:e24720.
[53] Adams S, Gray RJ, Demaria S, 
Goldstein L, Perez EA, Shulman LN, et 
al. Prognostic value of tumor-
infiltrating lymphocytes in triple-
negative breast cancers from two phase 
III randomized adjuvant breast cancer 
trials: ECOG 2197 and ECOG 1199. 
Journal of clinical oncology 
2014;32:2959.
[54] Adams S, Goldstein LJ, Sparano JA, 
Demaria S, Badve SS. Tumor infiltrating 
lymphocytes (TILs) improve prognosis 
in patients with triple negative breast 
cancer (TNBC). Oncoimmunology 
2015;4:e985930.
[55] Denkert C, Von Minckwitz G, 
Darb-Esfahani S, Heppner BI, 
Klauschen F, Furlanetto J, et al. Abstract 
S1-09: Evaluation of tumor-infiltrating 
lymphocytes (TILs) as predictive and 
prognostic biomarker in different 
subtypes of breast cancer treated with 
neoadjuvant therapy-A metaanalysis of 
3771 patients. AACR; 2017.
[56] Loi S, Schmid P, Aktan G, 
Karantza V, Salgado R. Relationship 
between tumor infiltrating lymphocytes 
(TILs) and response to pembrolizumab 
(pembro)+ chemotherapy (CT) as 
neoadjuvant treatment (NAT) for 
triple-negative breast cancer (TNBC): 
phase Ib KEYNOTE-173 trial. Annals of 
Oncology 2019;30:iii2.
[57] Thomas A, Routh ED, Pullikuth A, 
Jin G, Su J, Chou JW, et al. Tumor 
mutational burden is a determinant of 
immune-mediated survival in breast 
cancer. Oncoimmunology 
2018;7:e1490854.
[58] Marra A, Viale G, Curigliano G. 
Recent advances in triple negative breast 
cancer: the immunotherapy era. BMC 
medicine 2019;17:90.
[59] Samstein RM, Lee C-H, 
Shoushtari AN, Hellmann MD, Shen R, 
Janjigian YY, et al. Tumor mutational 
load predicts survival after 
immunotherapy across multiple cancer 
types. Nature genetics 2019;51:202-6.
[60] Quezada SA, Peggs KS. Exploiting 
CTLA-4, PD-1 and PD-L1 to reactivate 
the host immune response against 
31
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
DOI: http://dx.doi.org/10.5772/intechopen.100183
cancer. British journal of cancer 
2013;108:1560-5.
[61] Chemnitz JM, Parry RV, Nichols KE, 
June CH, Riley JL. SHP-1 and SHP-2 
associate with immunoreceptor 
tyrosine-based switch motif of 
programmed death 1 upon primary 
human T cell stimulation, but only 
receptor ligation prevents T cell 
activation. The Journal of Immunology 
2004;173:945-54.
[62] Sheppard K-A, Fitz LJ, Lee JM, 
Benander C, George JA, Wooters J, et al. 
PD-1 inhibits T-cell receptor induced 
phosphorylation of the ZAP70/CD3ζ 
signalosome and downstream signaling 
to PKCθ. FEBS letters 2004;574:37-41.
[63] Nanda R, Chow LQM, Dees EC, 
Berger R, Gupta S, Geva R, et al. 
Pembrolizumab in patients with 
advanced triple-negative breast cancer: 
phase Ib KEYNOTE-012 study. Journal 
of Clinical Oncology 2016;34:2460.
[64] Adams S, Schmid P, Rugo HS, 
Winer EP, Loirat D, Awada A, et al. 
Phase 2 study of pembrolizumab 
(pembro) monotherapy for previously 
treated metastatic triple-negative breast 
cancer (mTNBC): KEYNOTE-086 
cohort A. American Society of Clinical 
Oncology; 2017.
[65] Adams S, Loi S, Toppmeyer D, 
Cescon DW, De Laurentiis M, Nanda R, 
et al. Phase 2 study of pembrolizumab as 
first-line therapy for PD-L1–positive 
metastatic triple-negative breast cancer 
(mTNBC): preliminary data from 
KEYNOTE-086 cohort B. American 
Society of Clinical Oncology; 2017.
[66] Sabatier R, Finetti P, Mamessier E, 
Adelaide J, Chaffanet M, Ali HR, et al. 
Prognostic and predictive value of PDL1 
expression in breast cancer. Oncotarget 
2015;6:5449.
[67] Emens LA, Braiteh FS, Cassier P, 
Delord J-P, Eder JP, Fasso M, et al. 
Inhibition of PD-L1 by MPDL3280A 
leads to clinical activity in patients with 
metastatic triple-negative breast cancer 
(TNBC). AACR; 2015.
[68] Dirix LY, Takacs I, Jerusalem G, 
Nikolinakos P, Arkenau H-T, 
Forero-Torres A, et al. Avelumab, an 
anti-PD-L1 antibody, in patients with 
locally advanced or metastatic breast 
cancer: a phase 1b JAVELIN Solid Tumor 
study. Breast cancer research and 
treatment 2018;167:671-86.
[69] Sansom DM, Walker LSK. The role 
of CD28 and cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) in regulatory T-cell 
biology. Immunological reviews 
2006;212:131-48.
[70] Rudd CE, Taylor A, Schneider H. 
CD28 and CTLA-4 coreceptor 
expression and signal transduction. 
Immunological reviews 2009;229:12-26.
[71] Katz H, Alsharedi M. 
Immunotherapy in triple-negative 
breast cancer. Medical oncology 
2018;35:1-9.
[72] Ashburn TT, Thor KB. Drug 
repositioning: identifying and 
developing new uses for existing drugs. 
Nature reviews Drug discovery 
2004;3:673-83.
[73] Nosengo N. Can you teach old drugs 
new tricks? Nature News 2016;534:314.
[74] Aggarwal S, Verma SS, Aggarwal S, 
Gupta SC, editors. Drug repurposing for 
breast cancer therapy: Old weapon for 
new battle2021: Elsevier.
[75] Akhoon BA, Tiwari H, Nargotra A. 
In silico drug design methods for drug 
repurposing. In Silico Drug Design: 
Elsevier; 2019. p.47-84.
[76] Ávalos-Moreno M, López-Tejada A, 
Blaya-Cánovas JL, Cara-Lupiañez FE, 
González-González A, Lorente JA, et al. 
Drug repurposing for triple-negative 
Drug Repurposing - Molecular Aspects and Therapeutic Applications
32
breast cancer. Journal of Personalized 
Medicine 2020;10:200.
[77] Eid RA, Razavi GSE, Mkrtichyan M, 
Janik J, Khleif SN. Old-school 
chemotherapy in immunotherapeutic 
combination in cancer, a low-cost drug 
repurposed. Cancer immunology 
research 2016;4:377-82.
[78] Emens LA, Middleton G. The 
interplay of immunotherapy and 
chemotherapy: harnessing potential 
synergies. Cancer immunology research 
2015;3:436-43.
[79] Zitvogel L, Apetoh L, Ghiringhelli F, 
Kroemer G. Immunological aspects of 
cancer chemotherapy. Nature reviews 
immunology 2008;8:59-73.
[80] Schmid P, Adams S, Rugo HS, 
Schneeweiss A, Barrios CH, Iwata H, et 
al. Atezolizumab and nab-paclitaxel in 
advanced triple-negative breast cancer. 
New England Journal of Medicine 
2018;379:2108-21.
[81] Cortes J, Cescon DW, Rugo HS, 
Nowecki Z, Im S-A, Yusof MM, et al. 
Pembrolizumab plus chemotherapy 
versus placebo plus chemotherapy for 
previously untreated locally recurrent 
inoperable or metastatic triple-negative 
breast cancer (KEYNOTE-355): a 
randomised, placebo-controlled, 
double-blind, phase 3 clinical trial. The 
Lancet 2020;396:1817-28.
[82] Tolaney SM, Kalinsky K, 
Kaklamani V, Savulsky C, Olivo M, 
Aktan G, et al. Abstract PD6-13: Phase 
1b/2 study to evaluate eribulin mesylate 
in combination with pembrolizumab in 
patients with metastatic triple-negative 
breast cancer. AACR; 2018.
[83] Voorwerk L, Slagter M, 
Horlings HM, Sikorska K, van de 
Vijver KK, de Maaker M, et al. Immune 
induction strategies in metastatic 
triple-negative breast cancer to enhance 
the sensitivity to PD-1 blockade: the 
TONIC trial. Nature medicine 
2019;25:920-8.
[84] Adams S, Diamond JR, Hamilton E, 
Pohlmann PR, Tolaney SM, Chang C-W, 
et al. Atezolizumab plus nab-paclitaxel 
in the treatment of metastatic triple-
negative breast cancer with 2-year 
survival follow-up: a phase 1b clinical 
trial. JAMA oncology 2019;5:334-42.
[85] Loibl S, Untch M, Burchardi N, 
Huober J, Sinn BV, Blohmer JU, et al. A 
randomised phase II study investigating 
durvalumab in addition to an 
anthracycline taxane-based neoadjuvant 
therapy in early triple-negative breast 
cancer: clinical results and biomarker 
analysis of GeparNuevo study. Annals of 
Oncology 2019;30:1279-88.
[86] Mittendorf EA, Zhang H, 
Barrios CH, Saji S, Jung KH, Hegg R, et 
al. Neoadjuvant atezolizumab in 
combination with sequential nab-
paclitaxel and anthracycline-based 
chemotherapy versus placebo and 
chemotherapy in patients with early-
stage triple-negative breast cancer 
(IMpassion031): a randomised, double-
blind, phase 3 trial. The Lancet 
2020;396:1090-100.
[87] Nicolas E, Bertucci F, Sabatier R, 
Gonçalves A. Targeting BRCA 
deficiency in breast cancer: what are the 
clinical evidences and the next 
perspectives? Cancers 2018;10:506.
[88] Jiao S, Xia W, Yamaguchi H, Wei Y, 
Chen M-K, Hsu J-M, et al. PARP 
inhibitor upregulates PD-L1 expression 
and enhances cancer-associated 
immunosuppression. Clinical Cancer 
Research 2017;23:3711-20.
[89] Vinayak S, Tolaney SM, 
Schwartzberg L, Mita M, McCann G, 
Tan AR, et al. Open-label clinical trial of 
niraparib combined with 
pembrolizumab for treatment of 
advanced or metastatic triple-negative 
breast cancer. JAMA oncology 
2019;5:1132-40.
33
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
DOI: http://dx.doi.org/10.5772/intechopen.100183
[90] Zimmer AS, Nichols E, 
Cimino-Mathews A, Peer C, Cao L, Lee 
M-J, et al. A phase I study of the PD-L1 
inhibitor, durvalumab, in combination 
with a PARP inhibitor, olaparib, and a 
VEGFR1-3 inhibitor, cediranib, in 
recurrent women’s cancers with 
biomarker analyses. Journal for 
immunotherapy of cancer 2019;7:1-8.
[91] Finn RS, Martin M, Rugo HS, 
Jones S, Im S-A, Gelmon K, et al. 
Palbociclib and letrozole in advanced 
breast cancer. New England journal of 
medicine 2016;375:1925-36.
[92] Sledge Jr GW, Toi M, Neven P, 
Sohn J, Inoue K, Pivot X, et al. 
MONARCH 2: abemaciclib in 
combination with fulvestrant in women 
with HR+/HER2− advanced breast 
cancer who had progressed while 
receiving endocrine therapy. Journal of 
clinical oncology 2017;35:2875-84.
[93] Slamon DJ, Neven P, Chia S, 
Fasching PA, De Laurentiis M, Im S-A, 
et al. Phase III randomized study of 
ribociclib and fulvestrant in hormone 
receptor-positive, human epidermal 
growth factor receptor 2-negative 
advanced breast cancer: 
MONALEESA-3. J Clin Oncol 
2018;36:2465-72.
[94] Goel S, DeCristo MJ, Watt AC, 
BrinJones H, Sceneay J, Li BB, et al. 
CDK4/6 inhibition triggers anti-tumour 
immunity. Nature 2017;548:471-5.
[95] Deng J, Wang ES, Jenkins RW, Li S, 
Dries R, Yates K, et al. CDK4/6 
inhibition augments antitumor 
immunity by enhancing T-cell 
activation. Cancer discovery 
2018;8:216-33.
[96] Schaer DA, Beckmann RP, 
Dempsey JA, Huber L, Forest A, 
Amaladas N, et al. The CDK4/6 inhibitor 
abemaciclib induces a T cell inflamed 
tumor microenvironment and enhances 
the efficacy of PD-L1 checkpoint 
blockade. Cell reports 2018;22:2978-94.
[97] Tolaney SM, Kabos P, Dickler MN, 
Gianni L, Jansen V, Lu Y, et al. Updated 
efficacy, safety, & PD-L1 status of 
patients with HR+, HER2-metastatic 
breast cancer administered abemaciclib 
plus pembrolizumab. J Clin Oncol 
2018;36:1059.
[98] Hoeflich KP, O'Brien C, Boyd Z, 
Cavet G, Guerrero S, Jung K, et al. In 
vivo antitumor activity of MEK and 
phosphatidylinositol 3-kinase inhibitors 
in basal-like breast cancer models. 
Clinical Cancer Research 
2009;15:4649-64.
[99] Brufsky A, Kim S-B, Zvirbule Z, 
Dirix LY, Eniu AE, Carabantes F, et al. 
Phase II COLET study: Atezolizumab 
(A)+ cobimetinib (C)+ paclitaxel (P)/
nab-paclitaxel (nP) as first-line (1L) 
treatment (tx) for patients (pts) with 
locally advanced or metastatic triple-
negative breast cancer (mTNBC). 
American Society of Clinical 
Oncology; 2019.
[100] Rosenberg SA, Yang JC, Restifo NP. 
Cancer immunotherapy: moving 
beyond current vaccines. Nature 
medicine 2004;10:909-15.
[101] Sasada T, Noguchi M, Yamada A, 
Itoh K. Personalized peptide 
vaccination: a novel immunotherapeutic 
approach for advanced cancer. Human 
Vaccines & Immunotherapeutics 
2012;8:1309-13.
[102] Brahmer JR, Tykodi SS, 
Chow LQM, Hwu W-J, Topalian SL, 
Hwu P, et al. Safety and activity of 
anti–PD-L1 antibody in patients with 
advanced cancer. New England Journal 
of Medicine 2012;366:2455-65.
[103] Brahmer JR, Drake CG, Wollner I, 
Powderly JD, Picus J, Sharfman WH, et 
al. Phase I study of single-agent anti–
programmed death-1 (MDX-1106) in 
refractory solid tumors: safety, clinical 
activity, pharmacodynamics, and 
immunologic correlates. Journal of 
clinical oncology 2010;28:3167.
Drug Repurposing - Molecular Aspects and Therapeutic Applications
34
[104] Berger R, Rotem-Yehudar R, 
Slama G, Landes S, Kneller A, Leiba M, 
et al. Phase I safety and 
pharmacokinetic study of CT-011, a 
humanized antibody interacting with 
PD-1, in patients with advanced 
hematologic malignancies. Clinical 
Cancer Research 2008;14:3044-51.
[105] Topalian SL, Drake CG, 
Pardoll DM. Immune checkpoint 
blockade: a common denominator 
approach to cancer therapy. Cancer cell 
2015;27:450-61.
[106] Sharma P, Allison JP. Immune 
checkpoint targeting in cancer therapy: 
toward combination strategies with 
curative potential. Cell 2015;161:205-14.
[107] Weber JS, D'Angelo SP, Minor D, 
Hodi FS, Gutzmer R, Neyns B, et al. 
Nivolumab versus chemotherapy in 
patients with advanced melanoma who 
progressed after anti-CTLA-4 treatment 
(CheckMate 037): a randomised, 
controlled, open-label, phase 3 trial. The 
lancet oncology 2015;16:375-84.
[108] Shen H, Laird PW. Interplay 
between the cancer genome and 
epigenome. Cell 2013;153:38-55.
[109] Allis CD. Overview and Concepts 
In: Allis CD, Caparros ML, Jenuwein T, 
Reinberg D, Lachner M. Epigenetics. 
Cold Spring Harbor Laboratory Press, 
New York 2015:47-115.
[110] Shen H, Laird PW. In epigenetic 
therapy, less is more. Cell stem cell 
2012;10:353-4.
[111] Falkenberg KJ, Johnstone RW. 
Histone deacetylases and their inhibitors 
in cancer, neurological diseases and 
immune disorders. Nature reviews Drug 
discovery 2014;13:673-91.
[112] Stresemann C, Brueckner B, 
Musch T, Stopper H, Lyko F. Functional 
diversity of DNA methyltransferase 
inhibitors in human cancer cell lines. 
Cancer research 2006;66:2794-800.
[113] Rountree MR, Bachman KE, 
Baylin SB. DNMT1 binds HDAC2 and a 
new co-repressor, DMAP1, to form a 
complex at replication foci. Nature 
genetics 2000;25:269-77.
[114] Topper MJ, Vaz M, Marrone KA, 
Brahmer JR, Baylin SB. The emerging 
role of epigenetic therapeutics in 
immuno-oncology. Nature Reviews 
Clinical Oncology 2020;17:75-90.
[115] Baylin SB, Jones PA. A decade of 
exploring the cancer epigenome—
biological and translational 
implications. Nature Reviews Cancer 
2011;11:726-34.
[116] Baylin SB, Jones PA. Epigenetic 
determinants of cancer. Cold Spring 
Harbor perspectives in biology 
2016;8:a019505.
[117] Tsai H-C, Li H, Van Neste L, Cai Y, 
Robert C, Rassool FV, et al. Transient 
low doses of DNA-demethylating agents 
exert durable antitumor effects on 
hematological and epithelial tumor 
cells. Cancer cell 2012;21:430-46.
[118] Kaminskas E, Farrell A, 
Abraham S, Baird A, Hsieh L-S, Lee S-L, 
et al. Approval summary: azacitidine for 
treatment of myelodysplastic syndrome 
subtypes. Clinical cancer research 
2005;11:3604-8.
[119] Duvic M, Talpur R, Ni X, Zhang C, 
Hazarika P, Kelly C, et al. Phase 2 trial of 
oral vorinostat (suberoylanilide 
hydroxamic acid, SAHA) for refractory 
cutaneous T-cell lymphoma (CTCL). 
Blood 2007;109:31-9.
[120] VanderMolen KM, McCulloch W, 
Pearce CJ, Oberlies NH. Romidepsin 
(Istodax, NSC 630176, FR901228, 
FK228, depsipeptide): a natural product 
recently approved for cutaneous T-cell 
lymphoma. The Journal of antibiotics 
2011;64:525-31.
[121] Robert C, Rassool FV. HDAC 
inhibitors: roles of DNA damage and 
35
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
DOI: http://dx.doi.org/10.5772/intechopen.100183
repair. Advances in cancer research 
2012;116:87-129.
[122] Chiappinelli KB, Zahnow CA, 
Ahuja N, Baylin SB. Combining 
epigenetic and immunotherapy to 
combat cancer. Cancer research 
2016;76:1683-9.
[123] Juergens RA, Wrangle J, 
Vendetti FP, Murphy SC, Zhao M, 
Coleman B, et al. Combination 
epigenetic therapy has efficacy in 
patients with refractory advanced 
non–small cell lung cancer. Cancer 
discovery 2011;1:598-607.
[124] Wrangle J, Wang W, Koch A, 
Easwaran H, Mohammad HP, 
Vendetti F, et al. Alterations of immune 
response of non-small cell lung cancer 
with azacytidine. Oncotarget 
2013;4:2067.
[125] McGranahan N, Furness AJS, 
Rosenthal R, Ramskov S, Lyngaa R, 
Saini SK, et al. Clonal neoantigens elicit 
T cell immunoreactivity and sensitivity 
to immune checkpoint blockade. 
Science 2016;351:1463-9.
[126] Rizvi NA, Hellmann MD, 
Snyder A, Kvistborg P, Makarov V, 
Havel JJ, et al. Mutational landscape 
determines sensitivity to PD-1 blockade 
in non–small cell lung cancer. Science 
2015;348:124-8.
[127] James SR, Link PA, Karpf AR. 
Epigenetic regulation of X-linked 
cancer/germline antigen genes by 
DNMT1 and DNMT3b. Oncogene 
2006;25:6975-85.
[128] Li H, Chiappinelli KB, 
Guzzetta AA, Easwaran H, Yen R-WC, 
Vatapalli R, et al. Immune regulation by 
low doses of the DNA methyltransferase 
inhibitor 5-azacitidine in common 
human epithelial cancers. Oncotarget 
2014;5:587.
[129] Roulois D, Yau HL, Singhania R, 
Wang Y, Danesh A, Shen SY, et al. 
DNA-demethylating agents target 
colorectal cancer cells by inducing viral 
mimicry by endogenous transcripts. 
Cell 2015;162:961-73.
[130] Chiappinelli KB, Strissel PL, 
Desrichard A, Li H, Henke C, Akman B, 
et al. Inhibiting DNA methylation 
causes an interferon response in cancer 
via dsRNA including endogenous 
retroviruses. Cell 2015;162:974-86.
[131] Gang AO, Frøsig TM, Brimnes MK, 
Lyngaa R, Treppendahl MB, 
Grønbæk K, et al. 5-Azacytidine 
treatment sensitizes tumor cells to T-cell 
mediated cytotoxicity and modulates 
NK cells in patients with myeloid 
malignancies. Blood cancer journal 
2014;4:e197-e.
[132] Srivastava P, Paluch BE, 
Matsuzaki J, James SR, Collamat-Lai G, 
Blagitko-Dorfs N, et al. Induction of 
cancer testis antigen expression in 
circulating acute myeloid leukemia 
blasts following hypomethylating agent 
monotherapy. Oncotarget 2016;7:12840.
[133] Karpf AR. A potential role for 
epigenetic modulatory drugs in the 
enhancement of cancer/germ-line 
antigen vaccine efficacy. Epigenetics 
2006;1:116-20.
[134] Guo ZS, Hong JA, Irvine KR, 
Chen GA, Spiess PJ, Liu Y, et al. De novo 
induction of a cancer/testis antigen by 
5-aza-2′-deoxycytidine augments 
adoptive immunotherapy in a murine 
tumor model. Cancer research 
2006;66:1105-13.
[135] Kalac M, Scotto L, Marchi E, 
Amengual J, Seshan VE, Bhagat G, et al. 
HDAC inhibitors and decitabine are 
highly synergistic and associated with 
unique gene-expression and epigenetic 
profiles in models of DLBCL. Blood 
2011;118:5506-16.
[136] Yau HL, Ettayebi I, De 
Carvalho DD. The cancer epigenome: 
Drug Repurposing - Molecular Aspects and Therapeutic Applications
36
exploiting its vulnerabilities for 
immunotherapy. Trends in cell biology 
2019;29:31-43.
[137] Wang L, Amoozgar Z, Huang J, 
Saleh MH, Xing D, Orsulic S, et al. 
Decitabine enhances lymphocyte 
migration and function and synergizes 
with CTLA-4 blockade in a murine 
ovarian cancer model. Cancer 
immunology research 2015;3:1030-41.
[138] Stone ML, Chiappinelli KB, Li H, 
Murphy LM, Travers ME, Topper MJ, et 
al. Epigenetic therapy activates type I 
interferon signaling in murine ovarian 
cancer to reduce immunosuppression 
and tumor burden. Proceedings of the 
National Academy of Sciences 
2017;114:E10981-E90.
[139] Zheng H, Zhao W, Yan C, 
Watson CC, Massengill M, Xie M, et al. 
HDAC inhibitors enhance T-cell 
chemokine expression and augment 
response to PD-1 immunotherapy in 
lung adenocarcinoma. Clinical Cancer 
Research 2016;22:4119-32.
[140] Bommareddy PK, Shettigar M, 
Kaufman HL. Integrating oncolytic 
viruses in combination cancer 
immunotherapy. Nature Reviews 
Immunology 2018;18:498-513.
[141] Zamarin D, Holmgaard RB, 
Subudhi SK, Park JS, Mansour M, 
Palese P, et al. Localized oncolytic 
virotherapy overcomes systemic tumor 
resistance to immune checkpoint 
blockade immunotherapy. Science 
translational medicine 
2014;6:226ra32-ra32.
[142] Thomann S, Boscheinen JB, 
Vogel K, Knipe DM, DeLuca N, Gross S, 
et al. Combined cytotoxic activity of an 
infectious, but non-replicative herpes 
simplex virus type 1 and plasmacytoid 
dendritic cells against tumour cells. 
Immunology 2015;146:327-38.
[143] Mogensen TH. Pathogen 
recognition and inflammatory signaling 
in innate immune defenses. Clinical 
microbiology reviews 2009;22:240-73.
[144] Kaufman HL, Kohlhapp FJ, 
Zloza A. Oncolytic viruses: a new class 
of immunotherapy drugs. Nature 
reviews Drug discovery 2015;14:642-62.
[145] Haseley A, Alvarez-Breckenridge C, 
Chaudhury AR, Kaur B. Advances in 
oncolytic virus therapy for glioma. 
Recent Patents on CNS Drug Discovery 
(Discontinued) 2009;4:1-13.
[146] Fernandes J. Oncogenes: the 
passport for viral oncolysis through PKR 
inhibition. Biomarkers in cancer 
2016;8:BIC-S33378.
[147] Mounir Z, Krishnamoorthy JL, 
Robertson GP, Scheuner D, Kaufman RJ, 
Georgescu M-M, et al. Tumor 
suppression by PTEN requires the 
activation of the PKR-eIF2α 
phosphorylation pathway. Science 
signaling 2009;2:ra85-ra.
[148] Marsh M, Helenius A. Virus entry: 
open sesame. Cell 2006;124:729-40.
[149] Bommareddy PK, Kaufman HL. 
Unleashing the therapeutic potential of 
oncolytic viruses. The Journal of clinical 
investigation 2018;128:1258-60.
[150] Diana A, Wang LM, D'Costa Z, 
Allen P, Azad A, Silva MA, et al. 
Prognostic value, localization and 
correlation of PD-1/PD-L1, CD8 and 
FOXP3 with the desmoplastic stroma in 
pancreatic ductal adenocarcinoma. 
Oncotarget 2016;7:40992.
[151] Taube JM, Klein A, Brahmer JR, 
Xu H, Pan X, Kim JH, et al. Association 
of PD-1, PD-1 ligands, and other 
features of the tumor immune 
microenvironment with response to 
anti–PD-1 therapy. Clinical cancer 
research 2014;20:5064-74.
[152] Liu Z, Ravindranathan R, 
Kalinski P, Guo ZS, Bartlett DL. 
37
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
DOI: http://dx.doi.org/10.5772/intechopen.100183
Rational combination of oncolytic 
vaccinia virus and PD-L1 blockade 
works synergistically to enhance 
therapeutic efficacy. Nature 
communications 2017;8:1-12.
[153] Intlekofer AM, Thompson CB. At 
the bench: preclinical rationale for 
CTLA-4 and PD-1 blockade as cancer 
immunotherapy. Journal of leukocyte 
biology 2013;94:25-39.
[154] Bourgeois-Daigneault M-C, 
Roy DG, Aitken AS, El Sayes N, 
Martin NT, Varette O, et al. Neoadjuvant 
oncolytic virotherapy before surgery 
sensitizes triple-negative breast cancer 
to immune checkpoint therapy. Science 
translational medicine 2018;10.
[155] Kleinpeter P, Fend L, 
Thioudellet C, Geist M, Sfrontato N, 
Koerper V, et al. Vectorization in an 
oncolytic vaccinia virus of an antibody, 
a Fab and a scFv against programmed 
cell death-1 (PD-1) allows their 
intratumoral delivery and an improved 
tumor-growth inhibition. 
Oncoimmunology 2016;5:e1220467.
[156] Ilett E, Kottke T, Thompson J, 
Rajani K, Zaidi S, Evgin L, et al. Prime-
boost using separate oncolytic viruses in 
combination with checkpoint blockade 
improves anti-tumour therapy. Gene 
therapy 2017;24:21-30.
[157] Puzanov I, Milhem MM, Minor D, 
Hamid O, Li A, Chen L, et al. 
Talimogene laherparepvec in 
combination with ipilimumab in 
previously untreated, unresectable stage 
IIIB-IV melanoma. Journal of Clinical 
Oncology 2016;34:2619.
[158] Chaurasiya S, Yang A, Kang S, Lu J, 
Kim S-I, Park AK, et al. Oncolytic 
poxvirus CF33-hNIS-ΔF14. 5 favorably 
modulates tumor immune 
microenvironment and works 
synergistically with anti-PD-L1 
antibody in a triple-negative breast 
cancer model. Oncoimmunology 
2020;9:1729300.
[159] Mehraj U, Dar AH, Wani NA, 
Mir MA. Tumor microenvironment 
promotes breast cancer 
chemoresistance. Cancer chemotherapy 
and pharmacology 2021:1-12.
